Immune cell engagers and methods of use
SHARK molecules address the toxicities of cell therapies by inducing inactivation and death of immune effector cells through targeted engagement, effectively reducing harmful cell populations and alleviating symptoms.
Patent Information
- Application Number
- PCT/US2026/028216
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-01-30
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Cell therapies, such as chimeric antigen receptor (CAR)-T therapy, are associated with toxicities like cytokine release syndrome (CRS) due to the activation and expansion of immune effector cells.
Synthetic immune cell engagers, known as SHARK molecules, are designed to bring together two or more immune effector cells to induce inactivation and/or cell death, specifically targeting common antigens on these cells to reduce toxic populations driving toxicity or autoimmune diseases.
The SHARK molecules effectively inactivate or kill immune effector cells, alleviating therapy-associated toxicities and autoimmune symptoms by reducing the targeted cell populations.
Smart Images

Figure US2026028216_19112026_PF_FP_ABST
Abstract
Description
[0001] IMMUNE CELL ENGAGERS AND METHODS OF USE
[0002] RELATED APPLICATIONS
[0003] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63 / 806,478, filed May 15, 2025, entitled “Immune Cell Engagers and Methods of Use”, and U.S. Provisional Application No. 63 / 972,598, filed January 30, 2026, entitled “Immune Cell Engagers and Methods of Use,” the entire contents of each of which are incorporated herein by reference.
[0004] REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0005] The contents of the electronic sequence listing (M105370062WO00-SEQ-CNS.xml; Size: 83,353 bytes; and Date of Creation: May 12, 2026) are herein incorporated by reference in their entirety.
[0006] BACKGROUND
[0007] Cell therapy has revolutionized the treatment of some diseases and disorders. Some cell therapies engineer immune cells (e.g., host immune cells) to attack diseased cells in the host. For example, immune cells can be engineered to express a chimeric antigen receptor (CAR) or an engineered immune cell receptor that target a cell surface antigen of the cancer, thus directing the immune cell to the cancer. Some cell therapies are associated with toxicides.
[0008] SUMMARY
[0009] Cell therapy, such as chimeric antigen receptor (CAR)-T therapy, is often associated with toxicides, such as cytokine release syndrome (CRS) and other inflammatory syndromes.
[0010] Provided herein are synthetic immune cell engagers and methods of use thereof for inactivating and / or killing immune effector cells, e.g., immune effector cells that have been adoptively transferred into a subject to target diseased cells, such as cancer cells. The synthetic immune cell engagers of the disclosure (also referred to as Synthetic Homodimer / Heterodimer Activating Reciprocal Killing, or SHARK, molecules) can be used to bring two or more immune effector
[0011] #15201735vlcells together to induce inactivation and / or cell death of at least one of the immune effector cells. Such synthetic immune cell engagers are useful for removing immune effector cells that drive toxicides. They can also be useful for autoimmune diseases or disorders, for example by bringing together two or more autoreactive immune effector cells to induce inactivation and / or cell death of at least one of the autoreactive immune effector cells, thereby reducing the cell population driving the disease or disorder.
[0012] Accordingly, in some aspects, the disclosure provides a synthetic monospecific immune cell engager, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain and the second antigen-binding domain target the same immune cell antigen.
[0013] In some embodiments, the synthetic monospecific immune cell engager does not comprise an Fc region.
[0014] In some embodiments, the first antigen-binding domain and the second antigen-binding domain of the synthetic monospecific immune cell engager comprise the same amino acid sequence. In some embodiments, the synthetic monospecific immune cell engager is a homodimeric immune cell engager.
[0015] In some embodiments, the first antigen-binding domain and the second antigen-binding domain are linked by a linker. In some embodiments, the linker comprises a sequence of SEQ ID NO: 35 or 61.
[0016] In some embodiments, the immune cell antigen is an antigen expressed by a chimeric antigen receptor (CAR)-T cell, a T cell, a natural killer (NK) cell, a B cell, a macrophage, a mast cell, a neutrophil, a eosinophil, a basophil, a monocyte, or a dendritic cell.
[0017] In some aspects, the disclosure provides a synthetic monospecific immune cell engager comprising: a first antigen-binding domain comprising a VH, a (648)3 linker, and a VL; a G4S linker; and a second antigen-binding domain comprising a VH, a (648)3 linker; and a VL.
[0018] In some embodiments, the immune cell antigen is a camelid, FMC63, a 64S linker, a Whitlow linker, T cell receptor p chain- 1 (TRBC1), TRBC2, natural killer group 2 member D (NK62D), CD16A, CD206, or CD163.
[0019] In some embodiments, the first antigen-binding domain and the second antigen-binding domain comprise BCMA, CD 19, or a peptide-MHC complex.
[0020] In some embodiments, the synthetic monospecific immune cell engager comprises a sequence having at least 95% identity to the sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54. In some embodiments, the synthetic
[0021] #15201735vlmonospecific immune cell engager comprises a sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
[0022] In some embodiments, the disclosure provides a polynucleotide encoding a synthetic monospecific immune cell engager provided herein.
[0023] In some embodiments, the disclosure provides a method of linking two or more immune effector cells, the method comprising contacting the two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain that binds to a first immune effector cell antigen (IECA) and a second antigen-binding domain that binds to a second IECA.
[0024] In some embodiments, the first IECA and the second IECA each comprise one or more of a linker, a camelid, a T cell antigen, a chimeric antigen receptor (CAR)-T cell antigen, a natural killer (NK) cell antigen, a B cell antigen, a macrophage antigen, a mast cell antigen, a neutrophil antigen, a eosinophil antigen, a basophil antigen, a monocyte antigen and / or a dendritic cell antigen.
[0025] In some embodiments, the first IECA and the second IECA are the same. In some embodiments, the first IECA and the second IECA are different.
[0026] In some embodiments, the first antigen-binding domain and the second antigen-binding domain comprise the same amino acid sequence.
[0027] In some embodiments, the first antigen-binding domain and the second antigen-binding domain are linked by a linker. In some embodiments, the linker comprises a sequence of SEQ ID NO: 35 or 61.
[0028] In some embodiments, contacting the two or more immune cells with the synthetic immune cell engager inactivates the two or more immune cells. In some embodiments, contacting the two or more immune cells with the synthetic immune cell engager induces death of the two or more immune cells.
[0029] In some aspects, the disclosure provides a method of inducing immune effector cell death, the method comprising contacting two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain and a second antigen-binding domain.
[0030] In some aspects, the disclosure provides a method of inactivating two or more immune effector cells, the method comprising contacting the two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain and a second antigen-binding domain.
[0031] #15201735vlIn some embodiments, the two or more immune effector cells are selected from the group consisting of a T cell, a CAR-T cell, a NK cell, a B cell, a macrophage, a mast cell, a neutrophil, a eosinophil, a basophil, a monocyte, and a dendritic cell.
[0032] In some aspects, the disclosure provides a method of treating cell therapy-associated toxicity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a synthetic immune cell engager, wherein the synthetic immune cell engager comprises a first antigen-binding domain and a second antigen-binding domain.
[0033] In some embodiments, the first antigen-binding domain and / or the second antigenbinding domain binds to a camelid, FMC63, a G4S linker, a Whitlow linker, T cell receptor constant P chain-1 (TRBC1), TRBC2, natural killer group 2 member D (NKG2D), CD16A, CD206, or CD163.
[0034] In some embodiments, the first antigen-binding domain and / or the second antigenbinding domain comprise BCMA, CD 19, or a peptide-MHC complex.
[0035] In some embodiments, the synthetic immune cell engager comprises a sequence having at least 95% identity to the sequence of any one of SEQ ID NO: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54. In some embodiments, the synthetic immune cell engager comprises a sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
[0036] In some embodiments, the synthetic immune cell engager does not comprise an Fc region. In some embodiments, the synthetic immune cell engager does not comprise more than two antigen-binding domains.
[0037] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows activation of CAR-expressing Jurkat cells as measured by NF AT expression following coincubation with anti-G4S immune cell engagers (“SHARKs”).
[0038] FIG. 2 shows the response of CAR-T cells that structural (sequential) equivalents of FDA approved CAR-T cells Kymriah, yescarta, and breyanzi, and a non-FDA approved FMC63-bearing CAR.
[0039] FIG. 3 shows viable CAR+ cells remaining following incubation with increasing concentrations of G4S-targeting immune cell engagers.
[0040] #15201735vlFIG. 4 shows activation of Jurkat cells containing a camelid-based claudin 18.2 CAR, as measured by NFAT expression following coincubation with anti-VHH (anti-camelid) immune cell engagers.
[0041] FIG. 5 shows activation of CAR-T cells as measured by CD69 expression following coincubation with anti-VHH immune cell engagers.
[0042] FIG. 6 shows activation of clinical-grade CAR-T cells as measured by CD69 expression following coincubation with anti-FMC63 immune cell engagers.
[0043] FIGs. 7A-7D relate to the response of T cells expressing a FMC63-bearing CAR following treatment with increasing concentrations of anti-G4S immune cell engagers. FIG. 7A shows activation of CAR-T cells as measured by CD69 expression by immune cell engager concentration. FIG. 7B shows the percentage of live T cells following treatment with increasing doses of anti-G4S immune cell engagers. FIGs. 7C-7D relate to expression of the degranulation marker CD 107 a (FIG. 7C) and CD69 (FIG. 7D) in response to increasing concentrations of G4S immune cell engagers.
[0044] FIGs. 8A-8G relate to targeting of Jurkat T cells using anti-TRBCl immune cell engagers. Anti-TRBCl immune cell engagers were observed to activate Jurkat cells, as measured by NFAT expression (FIGs. 8A and 8D; comparing anti-TRBCl immune cell engager to negative control anti-camelid immune cell engager, FIG. 8A, or anti-TRBCl antibody, FIG.
[0045] 8D) and viability (FIGs. 8B-8C; comparing anti-TRBC 1 immune cell engager to negative control anti-camelid immune cell engager, FIG. 8B, or to anti-TRBCl antibody, FIG. 8C). Expression of the degranulation marker CD 107a (FIG. 8E) and the activation marker CD69 (FIG. 8F) was also measured. FIG. 8G shows NFAT expression in Jurkat cells incubated with anti-TRBCl immune cell engagers (“SHARK”) compared to cells incubated with anti-TRBCl antibody (“Ab”), as assessed by GFP expression as a marker of activation.
[0046] FIG. 9 relates to in vivo depletion of CAR-T cells using anti-TRBC 1 immune cell engagers.
[0047] FIGs. 10A-10D relate to binding of T cells bearing streptavidin-based CARs by biotinbased immune cell engagers having PEGylated multimer linkers of various lengths. Exemplary design schematics are shown in FIG. 10A (mechanism) and FIG. 10B (linker lengths). FIGs.
[0048] 10C-10D show CAR-T activation as measured by NFAT GFP expression in CAR-T cells (FIG.
[0049] 10C) versus untransduced (CAR ) T cells (FIG. 10D).
[0050] FIGs. 11A-11D relate to binding of anti- Whitlow immune cell engagers to CAR-T cells.
[0051] FIG. 11A shows activation of Jurkat cells bearing either a CAR that is the structural equivalent
[0052] #15201735vlof either kymriah (non- Whitlow linker) or breyanzi (Whitlow linker). FIG. 11B provides representative flow plots of activated CAR-T cells. FIGs. 11C-11D show granzyme B production (FIG. 11C) and TNF-a production (FIG. 11D) by CAR-T cells incubated with antiWhitlow immune cell engagers.
[0053] FIGs. 12A-12E relate to the binding of anti-TRBCl immune cell engagers to TRBC1+ T cells bearing anti-claudin 18.2 CARs. FIG. 12A shows the percentage of live CAR-T cells following incubation with anti-TRBCl immune cell engagers. Degranulation (FIG. 12B), apoptosis (FIG. 12C), and activation (FIG. 12D) of CAR-T cells was also assessed. FIG. 12E shows fluorescence labeling for active caspase-3 and -7 in CAR-T cells incubated with various concentrations of anti-TRBCl immune cell engagers.
[0054] FIG. 13 shows activation, as measured by mean fluorescence intensity (MFI) of NFAT-GFP expression in CAR-T cells incubated with anti-CD19 / anti-VHH heterodimeric immune cell engagers.
[0055] FIGs. 14A-14E relate to in vivo administration of anti-TRBCl immune cell engagers to mice engrafted with tumorigenic Jurkat (TRBC1+) cells. An exemplary experimental schematic is shown in FIG. 14A. FIG. 14B shows tumor growth, as measured by bioluminescent flux. FIG. 14C shows circulating tumor cells at day 21 post-administration of anti-TRBCl immune cell engagers. FIG. 14D shows change in body weight over time as a percentage of initial body weight. FIG. 14E is a survival curve.
[0056] FIG. 15 is an exemplary schematic of the mechanism of action of an immune cell engager provided herein.
[0057] FIG. 16 shows anti-G4S SHARK activity against G4S linker-bearing CAR-T constructs bearing the same amino acid sequence as kymriah and an FMC63-based CAR and Whitlow linker-bearing CAR-T constructs bearing the same amino acid sequence as yescarta and breyanzi.
[0058] FIG. 17 is an exemplary schematic of the mechanism of action of an immune cell engager provided herein and example effector molecules involved.
[0059] FIGs. 18A-18E relate to binding of anti-Whitlow immune cell engagers to CAR-T cells.
[0060] FIG. 18A shows the total number of live CAR-T cells after introduction of SHARKS at various dilutions relative to without SHARK treatment. FIGs. 18B-18E show functional metrics of CAR-T cell activity, including CD69 expression (FIG. 18B), degranulation (CD107a) (FIG. 18C), IFNg release (FIG. 18D), and perforin (FIG. 18E).
[0061] #15201735vlFIGs. 19A-19F relate to mechanisms of action of SHARK molecules. FIGs. 19A-19B show exemplary schematics of -activation (FIG. 19A) and / ra -activation (FIG. 19B) of CAR-T cells. FIG. 19C shows exemplary flow cytometry plots of granzyme B production by CAR-T cells treated with anti-linker SHARKS and anti-linker antibodies (exemplary flow plot shown in FIG. 19D). FIG. 19E shows a representative fluorescence microscopy image of SHARK-containing droplets, two of which contain cells exhibiting granzyme B activation (bottom-left). FIG. 19F is a bar graph of normalized trans- activation induced by anti-Whitlow SHARKS.
[0062] FIGs. 20A-20K demonstrate the role of Fc-mediated effector functions of anti-CAR antibodies. FIG. 20A is an exemplary experimental schematic. NSG mice are injected with 3 x 106CLDN18.2 CAR-T cells and receive anti-Whitlow antibody treatment one day later. FIG. 20B shows body weight as a percentage of starting body weight of mice treated as shown in FIG. 20A. FIG. 20C shows the number of CAR-T cells per mm2of glandular stomach of mice treated as shown in FIG. 20A. FIG. 20D is an exemplary schematic. NSG mice are injected with a toxic does of CLDN18.2 CAR-T cells (4 x 106) and beginning the following day receive saline or anti-Whitlow linker SHARKS (0.01 mg / day) delivered via a subcutaneously implanted osmotic pump. FIG. 20E shows the survival curve of mice treated as in FIG. 20D. FIG. 20F shows body weight as a percentage of starting body weight of mice treated as shown in FIG. 20D. FIG. 20G is the quantification of CAR-T cells per pL of blood. FIG. 20H is an exemplary schematic analogous to that shown in FIG. 20A, but mice are treated with an Fc-silenced anti-Whitlow linker antibody administered at an equimolar dose equivalent to 0.01 mg / day of SHARK. FIG. 201 shows the survival curve of mice treated as in FIG. 20E. FIG. 20J shows body weight as a percentage of starting body weight of mice treated as shown in FIG. 20D. FIG.
[0063] 20K is the quantification of CAR-T cells per pL of blood.
[0064] FIGs. 21A-21J relate to Fc-SHARK fusion molecules. FIG. 21A is an exemplary schematic showing a SHARK molecule without an Fc domain (left) and a SHARK molecule fused to an Fc domain (right). FIG. 21B shows body weight as a percentage of starting body weight of NSG mice untreated (UT) or injected with a toxic dose of CLDN18.2 CAR-T cells and receiving saline or anti-Whitlow linker SHARK-Fc molecules, administered at an equimolar dose corresponding to 0.003 mg / day of SHARK via a subcutaneously implanted osmotic pump.
[0065] FIG. 21C shows body weight as a percentage of starting body weight of NSG mice untreated (UT) or injected with 3 x 106anti-RORl CAR-T cells. FIG. 21D shows a survival curve of NSG mice from FIG. 21C. FIG. 21E shows bioluminescence imaging (BLI) of NSG mice injected
[0066] #15201735vlwith 3 x 106anti-RORl CAR-T cells expressing firefly luciferase. FIG. 21F are representative immunohistochemistry images showing anti-RORl CAR-T infiltration in lung, liver, spleen, and kidneys of treated NSG mice. FIG. 21 G shows body weight as a percentage of starting body weight of NSG mice untreated (UT) or injected with 10 x 106anti-RORl CAR-T cells and receiving either saline or anti- Whitlow SHARK-Fc molecules. FIG. 21H is the quantification of CAR-T cells in the peripheral blood of mice treated as in FIG. 21G. FIG. 211 shows body weight as a percentage of starting body weight of NSG mice untreated (UT) or injected with 3 x 106anti-GD2 (E101K) CAR-T cells and receiving either saline or anti- Whitlow SHARK-Fc molecules. FIG. 21J is the quantification of circulating CAR-T cells in mice treated as in FIG.
[0067] 211.
[0068] FIG. 22 shows CAR-T cell activation induced by SHARK molecules using two different VHH-binding domains.
[0069] FIG. 23 shows CAR-T cell activation by anti- Whitlow SHARK molecules using two different Whitlow-binding domains.
[0070] FIGs. 24A-24B relate to activation of TCRB2+ versus TCRB1+ anti-CD19 CAR-T cells following treatment with anti-TRBC2 SHARK molecules, as measured by the percentage of live cells (FIG. 24A) and CD69 expression (FIG. 24B).
[0071] FIGs. 25A-25D relate to the effect of anti-TRBC 1 SHARK molecules on bystander T cells. FIG. 25A shows cell count of tumor cells treated with T cells, anti-TRBC 1 SHARKS, or T cells with anti-TRBC 1 SHARKS. FIG. 25B is an exemplary experimental schematic. NSG mice are injected with 1 x 106Jurkat T-ALL cells and 1 week later injected with 3 x 106human T cells. One day later, mice begin to receive anti-TRBC 1 SHARK molecules daily at a dose of 0.001 mg / day. Peripheral blood is assessed at days 14, 21, and 28 post-Jurkat T-ALL engraftment. FIG. 25C shows the number of tumor cells in the blood of mice treated as in FIG.
[0072] 25B. FIG. 25D shows the fraction of TRBC1+ T cells and TRBC2+ T cells on day 14 of daily administration of anti-TRBC 1 -SHARK molecules.
[0073] FIGs. 26A-26G relate to anti-CAR antibody-mediated clearance of toxic CAR-T cells mediated by functional Fc engagement. FIG. 26A is an exemplary schematic of targetable epitopes across scFv- and VHH-based CAR constructs, including linkers and antigen-binding domains. FIG. 26B is an exemplary schematic of an Fc-inactivated (LALAPGNG mutations) anti-CAR antibody used as a comparator. FIG. 26C is an exemplary experimental schematic, in which NSG mice are administered a toxic dose (3 x 106cells) of Whitlow linker-bearing anti-Claudinl8.2 (CLDN1.2) CAR-T cells, followed by daily intravenous dosing of anti- Whitlow
[0074] #15201735vlantibodies or Fc-inactivated anti-Whitlow antibodies beginning 24h post-CAR-T engraftment. Mice are monitored for body weight changes and clinical toxicity. FIG. 26D shows the longitudinal body weight changes of mice from an experiment shown in FIG. 16C; dashed lines indicate baseline weight (100%) and 80% human endpoint threshold. Statistical significance was determined by two-way ANOVA. FIG. 26E is a Kaplan-Meier survival curve with significance assessed by log-rank (Mantel-Cox) test. FIG. 26F are representative immunohistochemistry images of glandular stomach (CLDN18.2+) tissues stained for human CD3 (hCD3) to detect CAR-T cell infiltration across treatment groups, quantified in FIG. 26G; quantification was performed from whole-slide imaging using QuPath for unbiased analysis.
[0075] FIGs. 27A-27O relate to potent CAR-T cell activation, fratricide, and in vivo protection driven by homodimeric SHARK-mediated trans cross-linking, independent of Fc function. FIG.
[0076] 27A is an exemplary schematic of a SHARK molecule targeting CAR linker domains, designed to enforce bivalent engagement and cross-linking of CARs between neighboring T cells. FIG.
[0077] 27B shows assays demonstrating functional comparison of SHARKS versus conventional antibodies; activation of Whitlow linker-bearing CAR Jurkat NFAT-GFP cells was assessed by GFP and CD69 expression following treatment with anti-Whitlow antibodies or SHARKS (two independent manufacturing lots). SHARKS induced significantly greater activation. P-values determined by extra sum-of-squares F-test. SHARK and antibody-treated CAR-T cells were evaluated for viability (FIG. 27C), activation (FIG. 27D), degranulation (CD107a) (FIG. 27E), granzyme B release (FIG. 27F), TNFa production (FIG. 27G), IFNy production (FIG. 27H), and perforin release (FIG. 271). Statistical comparisons were performed using two-way ANOVA with multiple hypothesis correction. FIG. 27J is representative serial live-cell tomography (Nanolive) imaging of Whitlow linker-bearing CAR-T cells (lisocabtagene maraleucel-like constructs) treated with anti-Whitlow SHARKS, demonstrating formation of immunological synapses between adjacent CAR-T cells followed by apoptosis of one engaged cell, as evidenced by caspase-3 / 7 activation. FIG. 27K shows quantification of normalized transactivation, calculated as [(% granzyme B+dual-cell droplets) - (% granzyme B+first dye-only) - (% granzyme B+ second dye-only)], demonstrating significantly enhanced trans activation by SHARK molecules relative to antibodies at 3h, 6h, and 24h. FIG. 27L is an exemplary experimental schematic; NSG mice are injected with 4 x 106Whitlow linker-bearing CLDN18.2 CAR-T cells. Id post-engraftment, mice receive continuous delivery of control (“sham”) of anti-Whitlow SHARK molecules (0.01 mg / day) via subcutaneous osmotic pump. Peripheral blood CAR-T expansion was measured at day 8, and mice were monitored for weight loss and clinical
[0078] #15201735vltoxicity. FIG. 27M show longitudinal body weight measurements, with dashed lines indicating baseline weight (100%) and 80% human endpoint threshold. FIG. 27N is a Kaplan-Meier survival curve (p-value determined by log-rank Mantel-Cox test). FIG. 270 shows absolute CAR-T cell counts in peripheral blood at day 8 (p-value determined by unpaired t-test).
[0079] FIGs. 28A-28T demonstrate that Fc-optimized SHARKS mitigate on-target, off-tumor toxicity across multiple CAR-T toxicity models and are effective when administered early after CAR-T infusion and at symptom onset. FIG. 28A is an exemplary schematic of a SHARK molecule fused to an Fc domain (“SHARK-Fc”); the format is designed to preserve intrinsic trans cross-linking and fratricide-inducing activity of SHARKS while extending serum half-life and enabling Fc-dependent pharmacologic properties in vivo. FIG. 28B is exemplary experimental schematic of prophylactic in vivo evaluation in a gastric toxicity model; NSG mice are administered a toxic dose (4 x 106) of Whitlow linker-bearing CLDN18.2 CAR-T cells. Beginning 24h post CAR-T infusion, mice receive continuous delivery of control (“sham”) or anti- Whitlow SHARK-Fc molecules via subcutaneous osmotic pump. Peripheral blood CAR-T expansion was assessed at days 7 and 14, and mice were monitored longitudinally for weight loss and clinical toxicity. FIG. 28C shows longitudinal body weight trajectories for mice from an experiment shown in FIG. 28B, with dashed lines indicating baseline weight (100%) and the 80% human endpoint threshold. FIG. 28D shows absolute CAR-T cell counts in peripheral blood at day 8, demonstrating reduced expansion with SHARK-Fc treatment (p-value determined by unpaired t-test). FIG. 28E is a quantification of human CD3+CAR-T cell infiltration in CLDN18.2+glandular stomach tissue by whole-slide imaging and unbiased QuPath analysis across treatment groups. FIG. 28F shows representative immunohistochemistry images corresponding to the results of FIG. 28E, demonstrating reduced CAR-T cell infiltration following SHARK-Fc treatment. FIG. 28G is an exemplary experimental schematic of prophylactic evaluation in a pulmonary toxicity model; NSG mice are administered a toxic dose (1 x 107) of Whitlow linker-bearing anti-RORl CAR-T cells. Sham or anti-Whitlow SHARK-Fc molecules are delivered continuously beginning 24h post-infusion. Peripheral blood CAR-T expansion is measured at days 7, 14, and 21, with concurrent monitoring of weight and clinical toxicity. FIG. 28H shows longitudinal body weight measurements for mice from an experiment shown in FIG. 28G, with dashed lines representing baseline (100%) body weight and the 80% human endpoint threshold. FIG. 281 shows absolute CAR-T cell counts in peripheral blood at day 8 (p-value determined by unpaired t-test), demonstrating early control of CAR-T expansion with SHARK-Fc. FIG. 28J is an exemplary experimental schematic of prophylactic evaluation
[0080] #15201735vlin a neurologic toxicity model; NSG mice receive a toxic dose (3 x 106) of high-affinity GD2 (El OIK) Whitlow linker-bearing CAR-T cells. Continuous delivery of sham or anti-Whitlow SHARK-Fc molecules is initiated 24h later. CAR-T expansion and clinical toxicity are monitored over time. FIG. 28K shows longitudinal body weight measurements for mice from an experiment shown in FIG. 28J. FIG. 28L is peripheral CAR-T expansion following treatment.
[0081] FIG. 28M is quantification of human CD3+CAR-T cell infiltration in brain and peripheral neural tissues by whole-slide imaging and QuPath-based analysis. FIG. 28N shows representative immunohistochemistry images corresponding to FIG. 28M, demonstrating reduced CAR-T accumulation in neural tissues with SHARK-Fc treatment. FIG. 280 is an exemplary experimental schematic of therapeutic (post-onset) intervention in a gastric toxicity model; NSG mice are administered a toxic dose (4 x 106cells) of CEDN18.2 CAR-T cells and monitored until development of clinical toxicity, defined by body weight loss beginning at day 7. Mice then receive daily intravenous dosing of sham or anti-Whitlow SHARK-Fc molecules for 7 consecutive days. FIG. 28P shows longitudinal body weight trajectories demonstrating reversal or stability of toxicity following delayed SHARK-Fc intervention, with dashed lines indication baseline (100%) body weight or the 80% humane endpoint threshold. FIG. 28Q is an exemplary schematic of an anti-camelid SHARK-Fc molecule designed to target VHH-based CAR constructs, such as those expressed in clinically relevant CAR constructs. FIG. 28R is an exemplary experimental schematic of a tumor model incorporating clinically relevant CAR-T therapy; NSG mice are engrafted with 1 x 106MM. Is luciferase-expressing multiple myeloma cells. Fourteen days later, mice receive 5 x 106BCMA-targeting CAR-T cells with the same amino acid sequence as iltacabtagene ciloleucel, or untransduced T cells (UTD). Beginning 24h after CAR-T infusion, mice are treated with continuous delivery of sham or anti-camelid SHARK-Fc molecules via osmotic pump. CAR-T expansion and tumor burden are monitored longitudinally by peripheral blood analysis and bioluminescent imaging. FIG. 28S shows absolute CAR-T cell counts in peripheral blood at day 7 (p-value determined by one-way ANOVA), demonstrating modulation of CAR-T expansion by SHARK-Fc molecules. FIG. 28T shows tumor burden over time, as measured by bioluminescence imaging, with statistical significance determined by two-way ANOVA, illustrating the balance between CAR-T control and preservation of anti-tumor activity.
[0082] FIGs. 29A-29H demonstrate that anti-TRBC 1 SHARK molecules selectively target clonal T-cell malignancies, inducing fratricide and durable tumor control while sparing normal TRBC2 repertoire. FIG. 29A is an exemplary schematic of an anti-TRBC 1 SHARK-Fc molecule
[0083] #15201735vldesigned to selectively target TRBC1 -expressing T cells. By exploiting the mutually exclusive expression of TRBC1 versus TRBC2 within the T-cell receptor p chain repertoire, this approach enables selective elimination of malignant clonal T-cell populations, while preserving a substantial fraction of normal T cells. FIG. 29B shows CAR-independent activation of Jurkat (TRBC1+) cells, quantified by NFAT-GFP expression after 16h of treatment with anti-TRBCl SHARK molecules or control SHARK molecules targeting an irrelevant antigen. FIG. 29C shows representative fluorescence microscopy images of Jurkat-GFP cells treated with anti-TRBC1 SHARK molecules for 72h. FIG. 29D is an exemplary experimental schematic of an in vivo efficacy model; NSG mice are engrafted with 1 x 106luciferase-labeled Jurkat T-ALL cells on day 0. Beginning on day 7, mice receive daily intravenous administration of anti-TRBCl SHARK molecules. FIG. 29E shows tumor burden over time, as measured by bioluminescence imaging, demonstrating significant tumor control with SHARK molecule treatment (p-value determined by two-way ANOVA). FIG. 29F is a Kaplan-Meier survival curve showing improved survival in SHARK-treated mice (p-value determined by log-rank Mantel-Cox test).
[0084] FIG. 29G is an exemplary experimental schematic of a continuous-delivery therapeutic model; NSG mice are engrafted with 1 x 106Jurkat T-ALL cells on day 0. Beginning on day 7, mice receive continuous subcutaneous delivery of sham or anti-TRBCl SHARK-Fc molecules via osmotic pump to evaluate sustained exposure and therapeutic efficacy. FIG. 29H shows longitudinal tumor burden, as assessed by bioluminescence imaging, demonstrating effective suppression of T-ALL growth with SHARK-Fc treatment (p-value determined by two-way ANOVA).
[0085] FIGs. 30A-30B relate to in vitro cytotoxicity of anti-TRBC2 SHARK molecules. FIG.
[0086] 30A is an exemplary schematic of isolation of TRBC1+ and TRBC2+ cells. FIG. 30B shows the percentage of live TRBC2+ (left) or TRBC1+ (right) cells treated with either anti-TRBC2 SHARKs or anti-TRBCl SHARKS, respectively.
[0087] DETAILED DESCRIPTION
[0088] Provided herein are synthetic immune cell engagers (also referred to as Synthetic Homodimer / Heterodimer Activating Reciprocal Killing (SHARK) molecules) and methods of using synthetic immune cell engagers. Such synthetic immune cell engagers are designed to target and bring together more than one immune cell (e.g., immune effector cell) to induce inactivation and / or cell death of one or more than one targeted immune cell (e.g., two immune
[0089] #15201735vleffector cells), for example in the context of cell therapy that has resulted in toxicity or autoimmune disease. By targeting of more than one immune cell (e.g., immune effector cell), the populations driving the toxicity or disease can be reduced, thereby alleviating or eliminating symptoms or side effects.
[0090] Synthetic Immune Cell Engagers
[0091] In some aspects, the disclosure provides a synthetic monospecific immune cell engager comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain and the second antigen-binding domain target the same immune cell antigen. A “synthetic immune cell engager” refers to an engineered molecule that targets (e.g., engages) two or more immune cells, thereby bringing the two or more immune cells together in close proximity, e.g., to induce inactivation and / or cell death of at least one of the immune cells. In some embodiments, synthetic immune cell engagers target domains that are common components of CARs or other immune cell populations, providing accessible, off-the-shelf compositions to selectively inactivate or deplete cells that are driving toxicity or disease.
[0092] As used herein, the term “antigen-binding domain” refers to a polypeptide that is sufficient to facilitate binding to a target. In some embodiments, a monospecific immune cell engager (e.g., an antigen binding domain of a monospecific immune cell engager) comprises a VH domain or a VHH domain. In some embodiments, a monospecific immune cell engager (e.g., an antigen binding domain of a monospecific immune cell engager) comprises a VH domain and a VL domain. The antigen-binding domain can specifically bind to its binding partner, i.e., the target. As non-limiting examples, the antigen-binding domain can include an antigen recognition domain of an antibody or antibody fragment (e.g., a Fab fragment, a F(ab')2 fragment, a Fv, or a scFv fragment), or a ligand, which recognizes and binds with a cognate binding partner protein. In this context, a ligand is a molecule that binds specifically to a portion of a protein and / or receptor. The cognate binding partner of a ligand useful in the methods and compositions described herein can generally be found on the surface of a cell. Ligand:cognate partner binding can result in the alteration of the ligand-bearing receptor, or activate a physiological response, for example, the activation or inactivation of a signaling pathway. In some embodiments, the ligand can be non-native to the genome. In some embodiments, the ligand has a conserved function across at least two species. A “first antigen-binding domain” refers to an antigen-binding domain that binds to a first antigen (e.g., of a first immune cell). A “second antigen-binding domain” refers to an antigen-binding domain that binds to a second
[0093] #15201735vlantigen (e.g., of a second immune cell). In some embodiments, the first antigen-binding domain and the second antigen-binding domain comprise different amino acid sequences. In some embodiments, the first antigen-binding domain and the second antigen-binding domain comprise the same amino acid sequence. In some embodiments, the first antigen-binding domain and the second antigen-binding domain bind the same epitope of an immune cell antigen. In some embodiments, the first antigen-binding domain and the second antigen-binding domain bind different epitopes of the same immune cell antigen. Where a first antigen-binding domain and a second antigen-binding domain bind the “same immune cell antigen”, it should be understood that they may not necessarily bind the same epitope on the immune cell antigen.
[0094] In some embodiments a first antigen-binding domain and / or a second antigen-binding domain comprises a ligand of an immune cell antigen. In some embodiments, the first antigenbinding domain and / or the second antigen-binding domain comprises BCMA, CD 19, and / or a peptide-MHC complex. In some embodiments, a first antigen-binding domain comprises a ligand and a second antigen-binding domain comprises an antibody or fragment thereof (e.g., an scFv). In some embodiments, a first antigen-binding domain comprises an antibody or fragment thereof (e.g., an scFv) and a second antigen-binding domain comprises a ligand.
[0095] In some embodiments, a synthetic monospecific immune cell engager comprises an antigen binding domain of any one of SEQ ID NOs: 2-33, 48-49, or 53.
[0096] In some embodiments, a synthetic monospecific immune cell engager is a homodimeric immune cell engager. A homodimeric immune cell engager comprises two antigen-binding domains that are identical in amino acid sequence. In some embodiments, a synthetic monospecific immune cell engager does not comprise more than two antigen-binding domains. In some embodiments, a homodimeric immune cell engager comprises two of the same antigen binding domain selected from any one of SEQ ID NOs: 2-33, 48-49, or 53.
[0097] In some embodiments, a synthetic monospecific immune cell engager provided herein comprises a sequence having at least 90% identity to the sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54. In some embodiments, a synthetic monospecific immune cell engager provided herein comprises a sequence having at least 95% identity to the sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54. In some embodiments, a synthetic monospecific immune cell engager provided herein comprises a sequence having at least 98% identity to the sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54. In some embodiments, a synthetic monospecific immune cell engager provided herein
[0098] #15201735vlcomprises a sequence having at least 99% identity to the sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54. In some embodiments, a synthetic monospecific immune cell engager provided herein comprises an amino acid sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
[0099] In some embodiments, a synthetic monospecific immune cell engager does not comprise an Fc region. An Fc region is a fragment of an antibody also called the constant region or constant domain. The Fc region is not part of the antigen-binding domain or region of an antibody and does not confer specificity of an antigen-binding domain for its cognate antigen.
[0100] In some embodiments, a synthetic monospecific immune cell engager comprises: a first antigen-binding domain comprising a variable heavy domain (VH), a (648)3 linker, and a variable light domain (VE); a G4S linker; and a second antigen-binding domain comprising a VH, a (648)3 linker, and a VL. In some embodiments, a VH comprises a sequence of any one of SEQ ID NOs: 36, 39, 42, 45, or 51. In some embodiments, a VL comprises a sequence of any one of SEQ ID NOs: 37, 40, 43, 46, or 51. In some embodiments, a VH comprises a sequence of SEQ ID NO: 36 and a VL comprises a sequence of SEQ ID NO: 37. In some embodiments, a VH comprises a sequence of SEQ ID NO: 39 and a VL comprises a sequence of SEQ ID NO: 40. In some embodiments, a VH comprises a sequence of SEQ ID NO: 42 and a VL comprises a sequence of SEQ ID NO: 43. In some embodiments, a VH comprises a sequence of SEQ ID NO: 45 and a VL comprises a sequence of SEQ ID NO: 46. In some embodiments, a VH comprises a sequence of SEQ ID NO: 50 and a VL comprises a sequence of SEQ ID NO: 51.
[0101] Fc Domains
[0102] In some embodiments, a synthetic monospecific immune cell engager of the disclosure comprises an Fc domain. Fc domains utilized in the prior art for immune cell engagers (e.g., bispecific T cell engagers) are typically modified to extend half-life of the engager while simultaneously abrogating or eliminating immune cell effector function typically conferred by addition of the Fc domain, to protect the engaged immune cell from cytotoxicity. Contrary to the practice in the prior art, the Fc domains fused to immune cell engagers of the present disclosure both extend the half-life of the immune cell engager and enhance immune cell effector function (e.g., are not modified to abrogate or eliminate immune cell effector function). In some embodiments, an Fc domain does not comprise a silencing mutation. As used herein, a “silencing mutation” refers to a mutation in the Fc domain that reduces or eliminates binding to Fc-gamma
[0103] #15201735vlreceptors, e.g., to abrogate or prevent immune cell function. Non-limiting examples of silencing mutations include a L234A / L235A (LALA) mutation, an N297G mutation, an N297A mutation, a L234A / L235A / P329G mutation, an L234A / L235A / G237A mutation, a L234A / L235A / P329G / N297G mutation, and a L234F / L235E / P331S mutation. Silencing mutations of Fc domains are known in the art (see, e.g., Hale et al., mAbs. 2024. 16(1):
[0104] 2402701). In some embodiments, synthetic monospecific immune cell engager of the disclosure comprises an Fc domain to enhance immune cell function.
[0105] In some embodiments, the Fc domain is fused to the synthetic monospecific immune cell engager via a linker. In some embodiments, the linker is a flexible linker. In some embodiments, the linker is a non-cleavable linker. In some embodiments, the linker is a glycine / serine linker. In some embodiments, the linker comprises the amino acid sequence of any one of SEQ ID NOs: 34-35 or 57.
[0106] In some embodiments, the Fc domain is an IgG, IgA, IgD, IgE, or IgM Fc domain. In some embodiments, the Fc domain is a human IgG, IgA, IgD, IgE, or IgM Fc domain. In some embodiments, the IgG Fc domain is an IgGl, IgG2, IgG3, or an IgG4 Fc domain. In some embodiments, the IgA Fc domain is an IgAl or an IgA2 Fc domain.
[0107] In some embodiments, the Fc domain comprises a mutation to extend half-life (e.g., by slowing or preventing immune cell engager reuptake) and / or enhance immune cell effector function (e.g., by enhancing binding of the Fc domain to an Fc-gamma receptor). In some embodiments, the Fc domain comprises a mutation to enhance immune cell effector function. Non-limiting examples of immune cell effector function include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complementdependent cytotoxicity (CDC). In some embodiments, the Fc domain is a Fc domain (e.g., a human Fc domain) comprising an S239D mutation, an I332E mutation, an S239D / I332E mutation, a G236A mutation, an A330L mutation, a G236A / S239D / A330L / I332E mutation, an S298A / E333A / K334A mutation, an E345K mutation, an E430G mutation, an S440Y mutation, an E345K / E430G mutation, an E430G / S440Y mutation, and / or an E345K / E430G / S440Y mutation in positions corresponding to a human IgGl Fc domain, wherein the position is determined according to EU numbering, also referred to as the EU index. EU numbering is often used to refer to a residue in an antibody constant region (e.g., a heavy chain constant region) and is well understood in the art see, e.g., Kabat et al. 1991, supra). Unless otherwise stated, an amino acid position of a constant region is designated herein according to EU numbering.
[0108] #15201735vlIn some embodiments, the Fc domain is a human IgGl Fc domain comprising an S239D mutation, an I332E mutation, an S239D / I332E mutation, a G236A mutation, and A330L mutation, a G236A / S239D / A330L / I332E mutation, an S298A / E333A / K334A mutation, an E345K mutation, an E430G mutation, an S440Y mutation, an E345K / E430G mutation, an E430G / S440Y mutation, or an E345K / E430G / S440Y mutation. In some embodiments, the Fc domain is a human IgGl Fc domain comprising an S239D mutation (see Oganesyan et al., Mol Immunol. 2008. 45(7): 1872-1882). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an I332E mutation (see Oganesyan et al., Mol Immunol. 2008. 45(7): 1872-1882). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an S239D / I332E mutation (see Oganesyan et al., Mol Immunol. 2008. 45(7): 1872-1882). In some embodiments, the Fc domain is a human IgGl Fc domain comprising a G236A mutation (see Richards et al., Mol Cancer Ther. 2008. 7(8): 2517-2527). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an A330L mutation (see Oganesyan et al., Mol Immunol.
[0109] 2008. 45(7): 1872-1882). In some embodiments, the Fc domain is a human IgGl Fc domain comprising a G236A / S239D / A330L / I332E mutation (e.g., a GASDALIE Fc; see Ahmed et al., J Struct Biol. 2016. 194(1): 78-89). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an S298A / E333A / K334A mutation (see Okazaki et al., J Mol Biol. 2004. 336(5): 1239-1249). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an E345K mutation (see Tammen et al., J Immunol. 2017. 198(4): 1585-1594). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an E430G mutation (see Tammen etal., J Immunol. 2017. 198(4): 1585-1594). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an S440Y mutation (see van Kampen et al., J Pharm Sci. 2022. 11(6): 1587-1598). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an E345K / E430G mutation (see van Kampen et al., J Pharm Sci. 2022. 11(6): 1587-1598). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an E430G / S440Y mutation (see van Kampen et al., J Pharm Sci. 2022. 11(6): 1587-1598). In some embodiments, the Fc domain is a human IgGl Fc domain comprising an E345K / E430G / S440Y mutation (see van Kampen et al., J Pharm Sci. 2022. 11(6): 1587-1598). In some embodiments, the Fc domain does not comprise a L234A, a L235A, a P329G, and / or a N297G mutation.
[0110] In some embodiments, the Fc domain comprises an amino acid sequence having at least 85% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises an amino acid sequence having at least 90% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises an amino acid
[0111] #15201735vlsequence having at least 92% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises an amino acid sequence having at least 95% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises an amino acid sequence having at least 97% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises an amino acid sequence having at least 98% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises an amino acid sequence having at least 99% identity to the sequence of any one of SEQ ID NOs: 62-71. In some embodiments, the Fc domain comprises the amino acid sequence of any one of SEQ ID NOs: 62-71.
[0112] In some embodiments, an Fc domain is linked to one scFv of a synthetic monospecific immune cell engager. In some embodiments, an Fc domain is linked to one scFv of a synthetic immune cell engager. In some embodiments, an Fc domain is linked to two scFvs of a synthetic monospecific immune cell engager. In some embodiments, an Fc domain is linked to two scFvs of a synthetic immune cell engager.
[0113] In some embodiments, an Fc domain is linked to a synthetic monospecific immune cell engager via a linker. In some embodiments, an Fc domain is linked to a synthetic immune cell engager via a linker. In some embodiments, a linker is a flexible linker. In some embodiments, a linker is a glycine- serine linker. In some embodiments, a linker comprises the amino acid sequence of any one of SEQ ID NOs: 34, 35, or 57. Any suitable linker (e.g., any linker described herein) can be used.
[0114] Immune Cell Antigens
[0115] In some aspects, the disclosure provides a synthetic monospecific immune cell engager that binds to an immune cell antigen. As used herein, an “immune cell antigen” is used interchangeably with an “immune effector cell antigen (IECA)”. In some embodiments, an immune cell antigen (e.g., the IECA) is an antigen expressed by a chimeric antigen receptor (CAR)-T cell, a T cell, a natural killer (NK) cell, a B cell, a macrophage, a mast cell, a neutrophil, a eosinophil, a basophil, a monocyte, or a dendritic cell. In some embodiments, an immune cell antigen (e.g., an IECA) comprises a camelid (e.g., VHH), FMC63, a G4S linker, a Whitlow linker, T cell receptor constant P chain-1 (TRBC1), TRBC2, natural killer group 2 member D (NKG2D), CD16A, CD206, or CD163. In some embodiments, an immune cell antigen can be any component of a CAR, including but not limited to an extracellular binding domain of a CAR (e.g., a component of an antibody comprised by the extracellular binding
[0116] #15201735vldomain), a linker of a CAR, a hinge domain of a CAR, and / or a transmembrane domain of a CAR.
[0117] Linkers
[0118] In some embodiments, a synthetic monospecific immune cell engager comprises a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain and the second antigen-binding domain are linked by a linker. As used herein, “linker” or “linker domain” refers molecule comprising a polymer (e.g., a peptide). In some embodiments, a linker comprises about 2 to 100 amino acids, which links together any of the domains / regions of the immune cell engagers as described herein. In some embodiment, linkers can include or be composed of flexible residues such as glycine and serine so that the adjacent protein domains are free to move relative to one another. Linker sequences useful for the invention can be from 2 to 100 amino acids, 5 to 50 amino acids, 10 to 15 amino acids, 15 to 20 amino acids, or 18 to 20 amino acids in length, and include any suitable linkers known in the art. In some embodiments, a linker is 12 amino acids in length. For instance, linker sequences useful for the invention include, but are not limited to, glycine / serine linkers, e.g., GGGGSGGGGSGGGGS (SEQ ID NO: 34), GGGGS (SEQ ID NO: 61), or GGGS (SEQ ID NO: 35). In some embodiments, the linker comprises the amino acid sequence of SEQ ID NO: 34. In some embodiments, the linker comprises the amino acid sequence of SEQ ID NO: 61. In some embodiments, a linker comprises the amino acid sequence of SEQ ID NO: 35. Longer linkers may be used when it is desirable to ensure that two adjacent domains do not sterically interfere with one another. Shorter linkers can also be used where necessary to facilitate targeting of an immune cell antigen by antigen binding domains. Linkers can also be cleavable (e.g., 2A linkers such as P2A or T2A linkers). In some embodiments, a linker is a length that is equivalent to the length of a PEG5 linker to the length of a PEG22 linker (inclusive). In some embodiments, a linker is a length that is equivalent to the length of a PEG8 linker to the length of a PEG16 linker (inclusive). In some embodiments, a linker is a length that is equivalent to the length of a PEG 10 linker to the length of a PEG 14 linker (inclusive). In some embodiments, a linker is a length that is equivalent to the length of a PEG 12 linker (inclusive). In some embodiments, a linker is 1-9 nm, 1-8 nm, 1-7 nm, 1-6 nm, 1-5 nm, 1-4 nm, 1-3 nm, or 1-2 nm in length. In some embodiments, a linker is 2-9 nm, 2-8 nm, 2-7 nm, 2-6 nm, 2-5 nm, 2-4 nm, or 2-3 nm. In some embodiments, a linker is 1-3 nm in length. In some embodiments, a linker is about 2 nm in length. In some embodiments, a linker is about 1 nm in length. In some
[0119] #15201735vlembodiments, a linker is about 3 nm in length. In some embodiments, a synthetic monospecific immune cell engager, comprises a first antibody fragment linked to a second antibody fragment with a first linker that is 1-4 nm (e.g., about 2 nm) in length, wherein the first antibody fragment and the second antibody fragment target the same immune cell antigen.
[0120] Polynucleotides
[0121] In some embodiments, the disclosure provides a polynucleotide encoding a synthetic monospecific immune cell engager. The term “polynucleotide” is used herein interchangeably with “nucleic acid molecule” to indicate a polymer of nucleosides. Typically, a polynucleotide is composed of nucleosides that are naturally found in DNA or RNA (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) joined by phosphodiester bonds. However, the term encompasses molecules comprising nucleosides or nucleoside analogs containing chemically or biologically modified bases, modified backbones, etc., whether or not found in naturally occurring nucleic acids, and such molecules may be preferred for certain applications. Where this disclosure refers to a polynucleotide, it is understood that both DNA, RNA, and in each case both single- and doublestranded forms (and complements of each single- stranded molecule) are provided.
[0122] “Polynucleotide sequence” as used herein can refer to the polynucleotide material itself and / or to the sequence information (i.e., the succession of letters used as abbreviations for bases) that biochemically characterizes a specific nucleic acid. In some embodiments, the nucleic acid molecule is a heterologous nucleic acid molecule. As used herein the term, “heterologous nucleic acid molecule” refers to a nucleic acid molecule that does not naturally exist within a given cell or a nucleic acid sequence that has been engineered into a cell. For example, a heterologous nucleic acid molecule may be a nucleic acid molecule encoding a gene that is engineered into a cell (e.g., via a plasmid, vector or some other method). A polynucleotide sequence presented herein is presented in a 5' to 3' direction unless otherwise indicated.
[0123] Methods
[0124] In some aspects, the disclosure provides a method of inducing immune effector cell death, the method comprising contacting two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain and a second-antigen binding domain. In some aspects, the disclosure provides a method of inactivating two or more immune effector cells, the method comprising contacting the two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain and a second
[0125] #15201735vlantigen-binding domain. In some aspects, the disclosure provides a method of treating cell therapy- associated toxicity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a synthetic immune cell engager, wherein the immune cell engager comprises a first antigen-binding domain and a second antigen-binding domain. Methods provided herein are useful for bringing two or more immune effector cells together to induce inactivation or immune effector cell death of at least one of the immune effector cells, for example to alleviate toxicides induced by cell therapy or autoimmune disease by depleting the population of toxicity-driving immune effector cells.
[0126] In some embodiments, a toxicity-driving immune effector cell is a CAR-T cell. In some embodiments, a toxicity-driving immune effector cell is selected from any one of idecabtagene vicleucel, lisocabtagene maraleucel, ciltacabtagene autoleucel, tisagenlecleucel, and axicabtagene ciloleucel. In some embodiments, a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) is administered to a subject who has received CAR-T therapy. In some embodiments, a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) is administered to a subject who is receiving CAR-T therapy. In some embodiments, a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) is administered to a subject who will receive CAR-T therapy.
[0127] In some embodiments, the disclosure provides a method of treating a T cell malignancy in a subject in need thereof, the method comprising administering a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) provided herein to the subject. In some embodiments, the T cell malignancy is selected from any one of T-lymphoblastic leukemia / lymphoma (T-ALL), peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), adult T-cell leukemia / lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), subcutaneous panniculitis-like T-cell lymphoma, hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lymphoma (EATL), T-cell large granular lymphocytic (LGL) leukemia, and T-cell prolymphocytic leukemia (T-PLL).
[0128] In some embodiments, administering comprises subcutaneous administration, intravenous administration, intraperitoneal administration, intranasal administration, or intramuscular administration.
[0129] In some embodiments, the two or more immune effect cells are selected from the group consisting of a T cell, a CAR-T cell, a NK cell, a B cell, a macrophage, a mast cell, a neutrophil, a eosinophil, a basophil, a monocyte, and a dendritic cell.
[0130] #15201735vlIn some embodiments of methods provided herein, the first antigen-binding domain and / or the second antigen-binding domain of a synthetic immune cell engager binds to a camelid (e.g., VHH), FMC63, a G4S linker, a Whitlow linker, T cell receptor constant P chain- 1 (TRBC1), TRBC2, natural killer group 2 member D (NKG2D), CD16A, CD206, or CD163. In some embodiments, the first antigen-binding domain and / or the second antigen-binding domain comprise BCMA, CD19, or a peptide-MHC complex. In some embodiments, the first antigenbinding domain and the second antigen-binding domain bind to different immune effector cell antigens. In some embodiments, the first antigen-binding domain and the second antigenbinding domain bind to the same immune effector cell antigen.
[0131] In some embodiments, the synthetic immune cell engager comprises a sequence having at least 90% identity to the sequence of any one of SEQ ID NO: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, or 31. In some embodiments, the synthetic immune cell engager comprises a sequence having at least 95% identity to the sequence of any one of SEQ ID NO: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, or 31. In some embodiments, the synthetic immune cell engager comprises a sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, or 31.
[0132] In some embodiments, the synthetic immune cell engager does not comprise an Fc region. In some embodiments, the synthetic immune cell engager does not comprise more than two antigen-binding domains.
[0133] The term “effective amount” includes the amount of synthetic immune cell engager administered to a subject. The term “therapeutically effective amount” therefore refers to an amount of synthetic immune cell engager described herein that is sufficient to provide a particular anti-condition effect when administered to a typical subject. An effective amount as used herein, in various contexts, would also include an amount sufficient to ameliorate symptoms of toxicity associated with cell therapy (e.g., to alleviate cytokine release syndrome, CRS) or to treat or alleviate symptoms of an autoimmune disease or disorder. A synthetic immune cell engager can be administered via any suitable route (e.g., transarterially, intravenously, intramuscularly, intratumorally, intranodally, intraperitoneally, intrathecally, intramedullary, or orally).
[0134] In some embodiments of methods provided herein, a synthetic immune cell engager comprises an Fc domain (e.g., as described elsewhere herein). In some embodiments, a synthetic immune cell engager used in a method provided herein comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 62-71. In
[0135] #15201735vlsome embodiments, an Fc domain comprises the amino acid sequence of any one of SEQ ID NOs: 62-71.
[0136] In some embodiments, administration of a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) provided herein to a subject results in decreased gastric toxicity in the subject compared to prior to administration. In some embodiments, administration of a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) provided herein to a subject results in decreased pulmonary toxicity in the subject compared to prior to administration. In some embodiments, administration of a synthetic immune cell engager (e.g., a synthetic monospecific immune cell engager) provided herein to a subject results in decreased neurotoxicity in the subject compared to prior to administration.
[0137] Table 1. Sequences
[0138] Name Sequence SEQ ID NO.
[0139] Anti-camelid ANIVMTQTPASVSGAVGGTVTIKCQASQSISTYLSWYQQKPGQPPKLLI 1 YQASELAYGVSSRFKGSGSGTEFTLTISGVECADAATYYCQQGYSDINV
[0140] (VHH)
[0141] DNFFGGGTEVWKGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLTLTC
[0142] immune cell TVSGFSLNNYTVIWVRQAPGKGLEWIGI IFGSGGTYYATWAEGRFTI SR
[0143] engager TSTTVDLKMTSPTTEDTATYFCARGYFGNTFWAMDPWGPGTLVTVSSGG GGSANIVMTQTPASVSGAVGGTVTIKCQASQSISTYLSWYQQKPGQPPK LLIYQASELAYGVSSRFKGSGSGTEFTLTISGVECADAATYYCQQGYSD INVDNFFGGGTEVWKGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLT LTCTVSGFSLNNYTVIWVRQAPGKGLEWIGI IFGSGGTYYATWAEGRFT ISRTSTTVDLKMTSPTTEDTATYFCARGYFGNTFWAMDPWGPGTLVTVS S
[0144] Anti-camelid ANIVMTQTPASVSGAVGGTVTIKCQASQSISTYLSWYQQKPGQPPKLLI 2 YQASELAYGVSSRFKGSGSGTEFTLTISGVECADAATYYCQQGYSDINV
[0145] (VHH) scFv
[0146] DNFFGGGTEVWKGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLTLTC
[0147] monomer TVSGFSLNNYTVIWVRQAPGKGLEWIGI IFGSGGTYYATWAEGRFTI SR TSTTVDLKMTSPTTEDTATYFCARGYFGNTFWAMDPWGPGTLVTVSS
[0148] Anti-FMC63 LKPREVKLVESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGL 3 EWIGEINLDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALY
[0149] immune cell
[0150] YCARRYDAMDYWGQGTSVTVSSASQGGGGSGGGGSGGGGSASDIVLTQS
[0151] engager PASLAVSLGQRATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYAAP NQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKDVRWRHQAG DQTGGGGSLKPREVKLVESGGGLVQPGGSLKLSCAASGFDFSRYWMSWV RQAPGKGLEWIGEINLDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKV RSEDTALYYCARRYDAMDYWGQGTSVTVSSASQGGGGSGGGGSGGGGSA SDIVLTQSPASLAVSLGQRATISCRASESVDDYGISFMNWFQQKPGQPP KLLI YAAPNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKD VRWRHQAGDQTG
[0152] Anti-FMC63 LKPREVKLVESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGL 4 EWIGEINLDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALY
[0153] scFv
[0154] YCARRYDAMDYWGQGTSVTVSSASQGGGGSGGGGSGGGGSASDIVLTQS
[0155] monomer PASLAVSLGQRATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYAAP
[0156]
[0157] #15201735vlNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKDVRWRHQAG DQT
[0158] Anti-G4S QSVKESGGRLVTPGTPLTLTCTVSGFSLSSNAIDWVRQAPGKGLEWIGI 5
[0159] LGRSGSTYYASWAKGRFTISRTSSTTVDLKITSPTTEDTATYFCARHFY immune cell
[0160] LWGPGTLVTVSSGTEGKSSGSGSESKSTAQVLTQTASPVSAAVGGTVTI engager NCQASQSVYSNYLSWYQQKPGQPPKLLMATTSTLEPGVPSRFKGSGSGT QFTLTISDLECDDAATYYCAGGYSVDIWVFGGGTEVWKGGGGSQSVKE SGGRLVTPGTPLTLTCTVSGFSLSSNAIDWVRQAPGKGLEWIGILGRSG STYYASWAKGRFTISRTSSTTVDLKITSPTTEDTATYFCARHFYLWGPG TLVTVSSGTEGKSSGSGSESKSTAQVLTQTASPVSAAVGGTVTINCQAS QSVYSNYLSWYQQKPGQPPKLLMATTSTLEPGVPSRFKGSGSGTQFTLT ISDLECDDAATYYCAGGYSVDIWVFGGGTEVWK
[0161] Anti-G4S QSVKESGGRLVTPGTPLTLTCTVSGFSLSSNAIDWVRQAPGKGLEWIGI 6
[0162] LGRSGSTYYASWAKGRFTISRTSSTTVDLKITSPTTEDTATYFCARHFY scFv
[0163] LWGPGTLVTVSSGTEGKSSGSGSESKSTAQVLTQTASPVSAAVGGTVTI monomer NCQASQSVYSNYLSWYQQKPGQPPKLLMATTSTLEPGVPSRFKGSGSGT QFTLTISDLECDDAATYYCAGGYSVDIWVFGGGTEVWK
[0164] Anti-Whitlow AYDMTQTPASVEVAVGGTVSIKCQASQSISTALAWYQQKPGQPPKLLIY 7
[0165] RASTLASGVSSRFKGSGSGTQFTLTISGVECDDAATYYCQQGWSTVNVD immune cell
[0166] NVFGGGTEVWRGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLTLTCT engager #1 AS GF T I SNLAI I WVRQAP GKGLE Y I GD I DGRGD I YC AT WAKGRF T I S KT STTLDLRFTSPTTEDTATYFCAVDGDGSGWGDFNFWGPGTLVTVSSGGG GSAYDMTQTPASVEVAVGGTVSIKCQASQSISTALAWYQQKPGQPPKLL IYRASTLASGVSSRFKGSGSGTQFTLTISGVECDDAATYYCQQGWSTVN VDNVFGGGTEVWRGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLTLT C T AS GF T I SNLAI I WVRQAP GKGLE Y I GD I DGRGD I YC AT WAKGRF T I S KTSTTLDLRFTSPTTEDTATYFCAVDGDGSGWGDFNFWGPGTLVTVSS
[0167] Anti-Whitlow AYDMTQTPASVEVAVGGTVSIKCQASQSISTALAWYQQKPGQPPKLLIY 8
[0168] RASTLASGVSSRFKGSGSGTQFTLTISGVECDDAATYYCQQGWSTVNVD scFv
[0169] NVFGGGTEVWRGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLTLTCT monomer 1 AS GF T I SNLAI I WVRQAP GKGLE Y I GD I DGRGD I YC AT WAKGRF T I S KT STTLDLRFTSPTTEDTATYFCAVDGDGSGWGDFNFWGPGTLVTVSS
[0170] Anti-TRBCl EVRLQQSGPDLIKPGASVKMSCKASGYTFTGYVMHWVKQRPGQGLEWIG 9
[0171] FINPYNDDIQSNERFRGKATLTSDKSSTTAYMELSSLTSEDSAVYYCAR immune cell
[0172] GAGYNFDGAYRFFDFWGQGTTLTVSSGGGGSGGGGSGGGGSDWMTQSP engager LSLPVSLGDQASISCRSSQRLVHSNGNTYLHWYLQKPGQSPKLLIYRVS NRFPGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQSTHVPYTFGGG TKLEIKRSDPGGGGSEVRLQQSGPDLIKPGASVKMSCKASGYTFTGYVM HWVKQRPGQGLEWIGFINPYNDDIQSNERFRGKATLTSDKSSTTAYMEL SSLTSEDSAVYYCARGAGYNFDGAYRFFDFWGQGTTLTVSSGGGGSGGG GSGGGGSDWMTQSPLSLPVSLGDQASISCRSSQRLVHSNGNTYLHWYL QKPGQSPKLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDLGIY FCSQSTHVPYTFGGGTKLEIKRSDP
[0173] Anti-TRBCl EVRLQQSGPDLIKPGASVKMSCKASGYTFTGYVMHWVKQRPGQGLEWIG 10
[0174] FINPYNDDIQSNERFRGKATLTSDKSSTTAYMELSSLTSEDSAVYYCAR scFv
[0175] GAGYNFDGAYRFFDFWGQGTTLTVSSGGGGSGGGGSGGGGSDWMTQSP monomer LSLPVSLGDQASISCRSSQRLVHSNGNTYLHWYLQKPGQSPKLLIYRVS NRFPGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQSTHVPYTFGGG TKLEIKRSDP
[0176]
[0177] #15201735vlAnti-TRBC2 QVQLVQ S GAE VKKP GAS VKVS CKAS T S GFHG YPMHWVRQAP GQGLE WMG 11 FINPYNDDIQSNERFRGRVTMTSDKSTTTAYMELSSLRSEDTAVYYCAR immune cell
[0178] GNGKWGDGAYRFFDFWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDW
[0179] engager #1 MTQSPLSLPVTPGEPASISCRSSQNLVHSNGRTYLQWYLQKPGQSPQLL IYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPY TFGGGTKVEIKGGGSQVQLVQSGAEVKKPGASVKVSCKASTSGFHGYPM HWVRQAPGQGLEWMGFINPYNDDIQSNERFRGRVTMTSDKSTTTAYMEL SSLRSEDTAVYYCARGNGKWGDGAYRFFDFWGQGTLVTVSSGGGGSGGG GSGGGGSGGGGSDWMTQSPLSLPVTPGEPASISCRSSQNLVHSNGRTY LQWYLQKPGQSPQLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAE DVGVYFCSQSTHVP YTFGGGTKVEIK
[0180] Anti-TRBC2 QVQLVQ S GAE VKKP GAS VKVS CKAS T S GFHG YPMHWVRQAP GQGLE WMG 12 FINPYNDDIQSNERFRGRVTMTSDKSTTTAYMELSSLRSEDTAVYYCAR scFv heavy
[0181] GNGKWGDGAYRFFDFWGQGTLVTVSS
[0182] chain
[0183] Anti-TRBC2 DVVMTQSPLSLPVTPGEPASISCRSSQNLVHSNGRTYLQWYLQKPGQSP 13 QLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTH scFv light
[0184] VP YTFGGGTKVEIK
[0185] chain
[0186] Anti-76 DIQMTQTTSILSASLGDRVTITCRASQDISNYLNWYQQNPDGTVKLLIY 14 YTSRLHSGVPSRFSGSGSGTEYSLTIKNLEQEDIATYFCQQGNMVPFTF immune cell
[0187] GSGTKLEIKGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVS engager GFSLTSYGVHWVRQPPGKGLEWLGVIWASGTTDYNSALMSRLTISKDNS KSQVFLRMNSLQTDDTAMYYCARETTASFGYWGLGTLVTVSAASGGGSD IQMTQTTSILSASLGDRVTITCRASQDISNYLNWYQQNPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTEYSLTIKNLEQEDIATYFCQQGNMVPFTFG SGTKLEIKGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSG FSLTSYGVHWVRQPPGKGLEWLGVIWASGTTDYNSALMSRLTISKDNSK SQVFLRMNSLQTDDTAMYYCARETTASFGYWGLGTLVTVSAAS
[0188] Anti-yS scFv DIQMTQTTSILSASLGDRVTITCRASQDISNYLNWYQQNPDGTVKLLIY 15 YTSRLHSGVPSRFSGSGSGTEYSLTIKNLEQEDIATYFCQQGNMVPFTF monomer
[0189] GSGTKLEIKGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVS GFSLTSYGVHWVRQPPGKGLEWLGVIWASGTTDYNSALMSRLTISKDNS KSQVFLRMNSLQTDDTAMYYCARETTASFGYWGLGTLVTVSAAS BCMA MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSV 16 KGTNAGGGGSANTGKVSNTVSANCYRQCTLPPTNSSCRLQCPICAHLLS immune cell
[0190] DFYENQSCQGAMQLM
[0191] engager
[0192] CD19 PEEPLWKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGL 17 PGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEG immune cell
[0193] SGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEI engager WEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWT HVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRG NLTMSFHLEI TARP VLWHWLLRTGGWKGGGGSKWGGTRLLWHWLVP RAT IELHFSMTLNGRHCYYKGADQATARPLLLGTEMVWMDRAPRDDKLELSL LSKPGKPHVHTWSLPGRSVSDPPVGCSLWLTSGPAMTLDQSLSQNLSDR PPLCPPEGEWIEPRDKAWVYLKPSMLKGSPSSPGESSRNKLGCGLGGLD SVNWRFLEGSGEVNVTWGPQWAKESPPGPQCLYFGGMQQSVNFIFLWIA LPRMHIGLGPLGLSLKLFPKLPSERSWTLQQTPGDSTGKLCQLVANDGE EVKWLPEEP
[0194]
[0195] #15201735vlHuman CD 19 PEEPLWKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGL 18 protein (N-to- PGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEG SGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEI C) WEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWT HVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRG NLTMSFHLEITARPVLWHWLLRTGGWK
[0196] Human CD 19 KWGGTRLLWHWLVPRATIELHFSMTLNGRHCYYKGADQATARPLLLGTE 19 protein (C-to- MVWMDRAPRDDKLELSLLSKPGKPHVHTWSLPGRSVSDPPVGCSLWLTS GPAMTLDQSLSQNLSDRPPLCPPEGEWIEPRDKAWVYLKPSMLKGSPSS N) PGESSRNKLGCGLGGLDSVNWRFLEGSGEVNVTWGPQWAKESPPGPQCL YFGGMQQSVNFIFLWIALPRMHIGLGPLGLSLKLFPKLPSERSWTLQQT PGDSTGKLCQLVANDGEEVKWLPEEP
[0197] Anti-NKG2D EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVS 20
[0198] SI SASGGSTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAK
[0199] immune cell
[0200] GIFS I YFFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL
[0201] engager #1 SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIKGG GGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLE WVS SI SASGGSTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYY CAKGIFSI YFFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEI K
[0202] Anti-NKG2D EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVS 21
[0203] SI SASGGSTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAK
[0204] variable
[0205] GIFSI YFFYFDYWGQGTLVTVSS
[0206] heavy domain
[0207] #1
[0208] Anti-NKG2D DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIY 22
[0209] AASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTF
[0210] variable light
[0211] GQGTKLEIK
[0212] domain #1
[0213] Anti-NKG2D EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVS 23
[0214] TISGSGSTTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAK
[0215] immune cell
[0216] GVFSEWHYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL
[0217] engager #2 SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIKGG GGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLE WVSTISGSGSTTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYY CAKGVFSEWHYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEI K
[0218] Anti-NKG2D EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVS 24
[0219] TISGSGSTTYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAK
[0220] variable
[0221] GVFSEWHYYFDYWGQGTLVTVSS
[0222] heavy domain
[0223] #1
[0224] Anti-NKG2D DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIY 25
[0225] AASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTF
[0226] variable light
[0227] GQGTKLEIK
[0228]
[0229] domain #2
[0230] #15201735vlAnti-CD16A EEVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLEWM 26 GT INPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA
[0231] immune cell
[0232] RGSAYYYDFADYWGQGTLVTVSSGGGGSGGGGSGGGGSQPVLTQPSSVS engager VAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQDNKRPSGIPER FSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFGGGTKLTVLGGG GSEEVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLE WMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYY CARGSAYYYDFADYWGQGTLVTVSSGGGGSGGGGSGGGGSQPVLTQPSS VSVAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQDNKRPSGIP ERFSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFGGGTKLTVL
[0233] Anti-CD16A EEVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLEWM 27
[0234] GT INPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA
[0235] variable
[0236] RGSAYYYDFADYWGQGTLVTVSS
[0237] heavy domain
[0238] Anti-CD16A QPVLTQPSSVSVAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQ 28
[0239] DNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFG
[0240] variable light
[0241] GGTKLTVL
[0242] domain
[0243] Anti-CD206 D VQLVE S GGGLVQP GGS LRL S CAAS GS I F T I NAMGW YRQAP GKQREE VA 29
[0244] AITSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCKAV
[0245] immune cell
[0246] WTTTPYSDYWGQGTLVTVSSGGGGSDVQLVESGGGLVQPGGSLRLSCA
[0247] engager ASGSIFTI NAMGW YRQAP GKQREE VAAI T S GGS TN YAD S VKGRF T I S RD NAKNTVYLQMNSLKPEDTAVYYCKAVWTTTPYSDYWGQGTLVTVSS
[0248] Anti-CD206 D VQLVE S GGGLVQP GGS LRL S CAAS GS I F T I NAMGW YRQAP GKQREE VA 30 VHH AITSGGSTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCKAV WTTTPYSDYWGQGTLVTVSS
[0249] Anti-CD163 E VQLVE S GGGWQP GRS LRL S CAAS GF TF S S YAMHWVRQAP GKGLE WVA 31
[0250] VI S YDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAR
[0251] immune cell
[0252] ENVRPYYDFWSGYYSEYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPS engager SKSTSGGTAALGCLVKDYFGGGGSGGGGSGGGGSDIQMTQSPSSLSASV GDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSG SGSGTDFTLTISSLQPEDFATYYCQQSYSTPRGTFGQGTKVEIKRGGGG S E VQLVE S GGGWQP GRS LRL S CAAS GF TF S S YAMHWVRQAP GKGLE WV AVIS YDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCA RENVRPYYDFWSGYYSEYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVKDYFGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRGTFGQGTKVEIKR
[0253] Anti-CD163 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIY 32
[0254] AASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRGT
[0255] variable light
[0256] FGQGTKVEIKR
[0257] chain
[0258] Anti-CD163 E VQLVE S GGGWQP GRS LRL S CAAS GF TF S S YAMHWVRQAP GKGLE WVA 33
[0259] VIS YDGSNKYYADSVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAR
[0260] variable
[0261] ENVRPYYDFWSGYYSEYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPS heavy chain SKSTSGGTAALGCLVKDYF
[0262] Linker 1 GGGGSGGGGSGGGGS 34 Linker 2 GGGGS 61 Anti-Whitlow QSVEESGGRLVTPGTPLTLTCTASGFTI SNLAI IWVRQAPGKGLEYIGD 36
[0263] IDGRGDIYCATWAKGRFTISKTSTTLDLRFTSPTTEDTATYFCAVDGDG
[0264] #1 scFv VH
[0265]
[0266] SGWGDFNFWGPGTLVTVSS
[0267] #15201735vlAnti-Whitlow AYDMTQTPASVEVAVGGTVSIKCQASQSISTALAWYQQKPGQPPKLLIY 37 RASTLASGVSSRFKGSGSGTQFTLTISGVECDDAATYYCQQGWSTVNVD
[0268] #1 scFv VL
[0269] NVFGGGTEVWR
[0270] Anti-Whitlow QSLEESGGRLVTPGTPLTLTCTVSGSDISSYHMGWVRQAPGKGLEYIGI 38
[0271] IVSSGSAYYATWAKGRFTISRTSTTVDLKITSPTTEDSATYFCARNQYS immune cell
[0272] GYGFSFWGPGTLVTVSSGGGGSGGGGSGGGGSWLTQTPSPVSTAVGGT
[0273] engager #2 VTINCQSSHSVYYGDWLAWYQQKPGQPPKLLI YRASNLASGVPSRFKGS GSGTQFTLTI SGVQCDDAATYYCLGGYDDDGETAFGGGTEVWKGGGGS QSLEESGGRLVTPGTPLTLTCTVSGSDISSYHMGWVRQAPGKGLEYIGI IVSSGSAYYATWAKGRFTISRTSTTVDLKITSPTTEDSATYFCARNQYS GYGFSFWGPGTLVTVSSGGGGSGGGGSGGGGSWLTQTPSPVSTAVGGT VTINCQSSHSVYYGDWLAWYQQKPGQPPKLLI YRASNLASGVPSRFKGS GSGTQFTLTI SGVQCDDAATYYCLGGYDDDGETAFGGGTEVWK
[0274] Anti-Whitlow WLTQTPSPVSTAVGGTVTINCQSSHSVYYGDWLAWYQQKPGQPPKLLI 39
[0275] YRASNLASGVPSRFKGSGSGTQFTLTISGVQCDDAATYYCLGGYDDDGE
[0276] #2 VH
[0277] TAFGGGTEVWK
[0278] Anti-Whitlow QSLEESGGRLVTPGTPLTLTCTVSGSDISSYHMGWVRQAPGKGLEYIGI 40 #2 VL IVSSGSAYYATWAKGRFTISRTSTTVDLKITSPTTEDSATYFCARNQYS GYGFSFWGPGTLVTVSS
[0279] Anti-TRBC2 QVQLVQ S GAE VKKP GAS VKVS CKAS P YGFHG YHMHWVRQAP GQGLE WMG 41
[0280] FINPYNDDIQSNERFRGRVTMTSDKSTTTAYMELSSLRSEDTAVYYCAR
[0281] immune cell
[0282] GNGKWGDGAYRFFDFWGQGTLVTVSSGGGGSGGGGSGGGGSDWMTQSP
[0283] engager #2 LSLPVTPGEPASISCRSSQNLKHRNGRTYLQWYLQKPGQSPQLLIYRVS NRFPGVPDRFSGSGSGTDFTLKI SRVEAEDVGVYFCSQSTHVP YTFGGG TKVEIKGGGGSQVQLVQSGAEVKKPGASVKVSCKASPYGFHGYHMHWVR QAPGQGLEWMGFINPYNDDIQSNERFRGRVTMTSDKSTTTAYMELSSLR SEDTAVYYCARGNGKWGDGAYRFFDFWGQGTLVTVSSGGGGSGGGGSGG GGSDWMTQSPLSLPVTPGEPASISCRSSQNLKHRNGRTYLQWYLQKPG QSPQLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQ STHVP YTFGGGTKVEIK
[0284] Anti-TRBC2 QVQLVQ S GAE VKKP GAS VKVS CKAS P YGFHG YHMHWVRQAP GQGLE WMG 42
[0285] FINPYNDDIQSNERFRGRVTMTSDKSTTTAYMELSSLRSEDTAVYYCAR VH GNGKWGDGAYRFFDFWGQGTLVTVSS
[0286] Anti-TRBC2 DVVMTQSPLSLPVTPGEPASISCRSSQNLKHRNGRTYLQWYLQKPGQSP 43
[0287] QLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTH VL VP YTFGGGTKVEIK
[0288] Anti-ySTCR DIQMTQTTSILSASLGDRVTITCRASQDISNYLNWYQQNPDGTVKLLIY 44
[0289] YTSRLHSGVPSRFSGSGSGTEYSLTIKNLEQEDIATYFCQQGNMVPFTF
[0290] immune cell
[0291] GSGTKLEIKGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVS engager GFSLTSYGVHWVRQPPGKGLEWLGVIWASGTTDYNSALMSRLTISKDNS KSQVFLRMNSLQTDDTAMYYCARETTASFGYWGLGTLVTVSAASGGGSD IQMTQTTSILSASLGDRVTITCRASQDISNYLNWYQQNPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTEYSLTIKNLEQEDIATYFCQQGNMVPFTFG SGTKLEIKGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSG FSLTSYGVHWVRQPPGKGLEWLGVIWASGTTDYNSALMSRLTISKDNSK SQVFLRMNSLQTDDTAMYYCARETTASFGYWGLGTLVTVSAAS
[0292] Anti-ySTCR QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYGVHWVRQPPGKGLEWLG 45
[0293] VI WASGTTDYNSALMSRLTI SKDNSKSQVFLRMNSLQTDDTAMYYCARE VH TTASFGYWGLGTLVTVSAA
[0294]
[0295] #15201735vlAnti-ySTCR DIQMTQTTSILSASLGDRVTITCRASQDISNYLNWYQQNPDGTVKLLIY 46 YTSRLHSGVPSRFSGSGSGTEYSLTIKNLEQEDIATYFCQQGNMVPFTF VL GSGTKLEIK CD19 / anti- PEEPLWKVEEGDEAWLPCLKGTSDGPTQQLTWSRESPLKPFLKVSFGV 47
[0296] PGLGVHVRPNAVSLVISNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEG
[0297] Whitlow
[0298] SGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEI immune cell WEGEPPCLPPRDSLNQSLSRDMTVAPGSTLWLSCGVPPDSVSRGPLSWT engager HVHPKGPKSLLSLELKDDRPARDMWVTGTRLFLPRATAQDAGKYYCHRG NLTMSFHLEVKARPVSAHTKLRTGGWKGGGGSMETGLRWLLLVAVLKGV QCQSLEESGGRLVTPGTPLTLTCTVSGSDISSYHMGWVRQAPGKGLEYI GI IVSSGSAYYATWAKGRFTI SRTSTTVDLKITSPTTEDSATYFCARNQ YSGYGFSFWGPGTLVTVSSGGGGSGGGGSGGGGSMDTRAPTQLLGLLLL WLPGATFAWLTQTPSPVSTAVGGTVTINCQSSHSVYYGDWLAWYQQKP GQPPKLLIYRASNLASGVPSRFKGSGSGTQFTLTISGVQCDDAATYYCL GGYDDDGETAFGGGTEVWK CD19 PEEPLWKVEEGDEAWLPCLKGTSDGPTQQLTWSRESPLKPFLKVSFGV 48 extracellular PGLGVHVRPNAVSLVISNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEG SGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEI domain WEGEPPCLPPRDSLNQSLSRDMTVAPGSTLWLSCGVPPDSVSRGPLSWT HVHPKGPKSLLSLELKDDRPARDMWVTGTRLFLPRATAQDAGKYYCHRG NLTMSFHLEVKARPVSAHTKLRTGGWK
[0299] Anti-Whitlow METGLRWLLLVAVLKGVQCQSLEESGGRLVTPGTPLTLTCTVSGSDISS 49
[0300] YHMGWVRQAPGKGLEYIGIIVSSGSAYYATWAKGRFTISRTSTTVDLKI linker scFv
[0301] TSPTTEDSATYFCARNQYSGYGFSFWGPGTLVTVSSGGGGSGGGGSGGG GSMDTRAPTQLLGLLLLWLPGATFAWLTQTPSPVSTAVGGTVTINCQS SHSVYYGDWLAWYQQKPGQPPKLLI YRASNLASGVPSRFKGSGSGTQFT LTISGVQCDDAATYYCLGGYDDDGETAFGGGTEVWK
[0302] Clone 16 VH METGLRWLLLVAVLKGVQCQSLEESGGRLVTPGTPLTLTCTVSGSDISS 50
[0303] YHMGWVRQAPGKGLEYIGIIVSSGSAYYATWAKGRFTISRTSTTVDLKI TSPTTEDSATYFCARNQYSGYGFSFWGPGTLVTVSS
[0304] Clone 16 VL MDTRAPTQLLGLLLLWLPGATFAWLTQTPSPVSTAVGGTVTINCQSSH 51
[0305] SVYYGDWLAWYQQKPGQPPKLLIYRASNLASGVPSRFKGSGSGTQFTLT I SGVQCDDAATYYCLGGYDDDGETAFGGGTEVWK BCMA / anti- LQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVK 52
[0306] GTNAGGGGSANIVMTQTPASVSGAVGGTVTIKCQASQSISTYLSWYQQK
[0307] camelid
[0308] PGQPPKLLIYQASELAYGVSSRFKGSGSGTEFTLTISGVECADAATYYC
[0309] (VHH) QQGYSDINVDNFFGGGTEVWKGGGGSGGGGSGGGGSQSVEESGGRLVT immune cell PGTPLTLTCTVSGFSLNNYTVIWVRQAPGKGLEWIGI IFGSGGTYYATW engager AEGRFTISRTSTTVDLKMTSPTTEDTATYFCARGYFGNTFWAMDPWGPG TLVTVSS BCMA LQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVK 53
[0310] GTNA
[0311] extracellular
[0312] domain
[0313] CD19 / anti- PEEPLWKVEEGDEAWLPCLKGTSDGPTQQLTWSRESPLKPFLKVSFGV 54
[0314] PGLGVHVRPNAVSLVISNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEG
[0315] camelid
[0316] SGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEI (VHH) WEGEPPCLPPRDSLNQSLSRDMTVAPGSTLWLSCGVPPDSVSRGPLSWT immune cell HVHPKGPKSLLSLELKDDRPARDMWVTGTRLFLPRATAQDAGKYYCHRG engager NLTMSFHLEVKARPVSAHTKLRTGGWKGGGSGGGSGGGSGGGSANIVMT
[0317] QTPASVSGAVGGTVTIKCQASQSISTYLSWYQQKPGQPPKLLIYQASEL
[0318]
[0319] #15201735vlAYGVSSRFKGSGSGTEFTLTISGVECADAATYYCQQGYSDINVDNFFGG GTEVWKGGGGSGGGGSGGGGSQSVEESGGRLVTPGTPLTLTCTVSGFS LNNYTVIWVRQAPGKGLEWIGIIFGSGGTYYATWAEGRFTISRTSTTVD LKMTSPTTEDTATYFCARGYFGNTFWAMDPWGPGTLVTVSS
[0320] Anti-Whitlow QSLEESGGRLVTPGTPLTLTCTVSGSDISSYHMGWVRQAPGKGLEYIGI 55
[0321] IVSSGSAYYATWAKGRFTISRTSTTVDLKITSPTTEDSATYFCARNQYS
[0322] Fc-fused
[0323] GYGFSFWGPGTLVTVSSGGGGSGGGGSGGGGSWLTQTPSPVSTAVGGT immune cell VTINCQSSHSVYYGDWLAWYQQKPGQPPKLLI YRASNLASGVPSRFKGS engager GSGTQFTLTI SGVQCDDAATYYCLGGYDDDGETAFGGGTEVWKGGGGS QSLEESGGRLVTPGTPLTLTCTVSGSDISSYHMGWVRQAPGKGLEYIGI IVSSGSAYYATWAKGRFTISRTSTTVDLKITSPTTEDSATYFCARNQYS GYGFSFWGPGTLVTVSSGGGGSGGGGSGGGGSWLTQTPSPVSTAVGGT VTINCQSSHSVYYGDWLAWYQQKPGQPPKLLI YRASNLASGVPSRFKGS GSGTQFTLTI SGVQCDDAATYYCLGGYDDDGETAFGGGTEVWKGGGGS GGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPI VTCVWDVSEDDPDVQI SWFVNNVEVHTAQTQTHREDYNSTLRWSALP IQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEE EMTKKQVTLTCMVTDFMPEDI YVEWTNNGKTELNYKNTEPVLDSDGS YF MYSKLRVEKKNWVERNSYSCSWHEGLHNHHTTKSFSRTPGKGGGGSGG GGSGGGGSGGGGSGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSV FI FPPKIKDVLMI SLSP I VTCVWDVSEDDPDVQI SWFVNNVEVHTAQT QTHREDYNSTLRWSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISK PKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDI YVEWTNNGKT ELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSWHEGLHNHH TTKSFSRTPGK
[0324] Murine Fc EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCW 56
[0325] VDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRWSALPIQHQD
[0326] IgG2a domain
[0327] WMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK QVTLTCMVTDFMPEDI YVEWTNNGKTELNYKNTEPVLDSDGS YFMYSKL RVEKKNWVERNSYSCSWHEGLHNHHTTKSFSRTPGKGGGGSGGGGSGG GGSGGGGSGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPP KI KDVLMI SLSP I VTCVWDVSEDDPDVQI SWFVNNVEVHTAQTQTHRE DYNSTLRWSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSV RAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDI YVEWTNNGKTELNYK NTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSWHEGLHNHHTTKSF SRTPGK
[0328] Linker-3 GGGGSGGGGS 57 Anti-TRBCl EVRLQQSGPDLIKPGASVKMSCKASGYTFTGYVMHWVKQRPGQGLEWIG 58
[0329] FINPYNDDIQSNERFRGKATLTSDKSSTTAYMELSSLTSEDSAVYYCAR
[0330] Fc-fused
[0331] GAGYNFDGAYRFFDFWGQGTTLTVSSGGGGSGGGGSGGGGSDWMTQSP immune cell LSLPVSLGDQASISCRSSQRLVHSNGNTYLHWYLQKPGQSPKLLIYRVS engager NRFPGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQSTHVPYTFGGG TKLEIKRSDPGGGGSEVRLQQSGPDLIKPGASVKMSCKASGYTFTGYVM HWVKQRPGQGLEWIGFINPYNDDIQSNERFRGKATLTSDKSSTTAYMEL SSLTSEDSAVYYCARGAGYNFDGAYRFFDFWGQGTTLTVSSGGGGSGGG GSGGGGSDWMTQSPLSLPVSLGDQASISCRSSQRLVHSNGNTYLHWYL QKPGQSPKLLIYRVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDLGIY FCSQSTHVPYTFGGGTKLEIKRSDPGGGGSEPRGPTIKPCPPCKCPAPN LLGGP SVFIFPPKIKD VLMI SLSP I VTCVWDVSEDDPDVQI SWFVNNV EVHTAQTQTHREDYNSTLRWSALPIQHQDWMSGKEFKCKVNNKDLPAP IERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVE
[0332]
[0333] #15201735vlWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSWH EGLHNHHTTKSFSRTPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSE PRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVW DVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRWSALPIQHQDW MSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ VTLTCMVTDFMPEDI YVEWTNNGKTELNYKNTEPVLDSDGS YFMYSKLR VEKKNWVERNSYSCSWHEGLHNHHTTKSFSRTPGK
[0334] Anti-VHH QSVEESGGRLVTPGTPLTLTCTVSGFSLRNFAMSWVRQAPGKGLEWIGI 59
[0335] IYSGGTRDYATWAKGRFTISKTSTTVDLKMTSPTTEDTATYFCARDRSP immune cell
[0336] DYSAAFLLWGQGTLVTVSSGGGGSGGGGSGGGGSIVMTQTPSSKSVPVG engager #2 DTVTINCQASESVYSNNHLAWFQQKPGQPPKLLI YSASTLESGVPSRFK GSGSGTQFTLTISGVQCDDAATYYCAGYKSSDTDGTSFGGGTEVWKGG GGSQSVEESGGRLVTPGTPLTLTCTVSGFSLRNFAMSWVRQAPGKGLEW I G 11 Y S GGTRD YAT WAKGRF T I S KT S T T VD LKMT S P T TED T AT YFC ARD RSPDYSAAFLLWGQGTLVTVSSGGGGSGGGGSGGGGSIVMTQTPSSKSV PVGDTVTINCQASESVYSNNHLAWFQQKPGQPPKLLI YSASTLESGVPS RFKGSGSGTQFTLTISGVQCDDAATYYCAGYKSSDTDGTSFGGGTEVW K
[0337] Anti-VHH QSVEESGGRLVTPGTPLTLTCTVSGFSLRNFAMSWVRQAPGKGLEWIGI 60
[0338] IYSGGTRDYATWAKGRFTISKTSTTVDLKMTSPTTEDTATYFCARDRSP immune cell
[0339] DYSAAFLLWGQGTLVTVSSGGGGSGGGGSGGGGSIVMTQTPSSKSVPVG engager #2, DTVTINCQASESVYSNNHLAWFQQKPGQPPKLLI YSASTLESGVPSRFK Fc-fused GSGSGTQFTLTISGVQCDDAATYYCAGYKSSDTDGTSFGGGTEVWKGG GGSQSVEESGGRLVTPGTPLTLTCTVSGFSLRNFAMSWVRQAPGKGLEW IGIIYS GGTRD YAT WAKGRF T I S KT S T T VD LKMT S P T TED TAT YFC ARD RSPDYSAAFLLWGQGTLVTVSSGGGGSGGGGSGGGGSIVMTQTPSSKSV PVGDTVTINCQASESVYSNNHLAWFQQKPGQPPKLLI YSASTLESGVPS RFKGSGSGTQFTLTISGVQCDDAATYYCAGYKSSDTDGTSFGGGTEVW KGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLM ISLSPIVTCVWDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLR WSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYV LPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLD SDGSYFMYSKLRVEKKNWVERNSYSCSWHEGLHNHHTTKSFSRTPGKG GGGSGGGGSGGGGSGGGGSGGGGSGGGGSEPRGPTIKPCPPCKCPAPNL LGGPSVFIFPPKIKDVLMISLSPIVTCVWDVSEDDPDVQISWFVNNVE VHTAQTQTHREDYNSTLRWSALPIQHQDWMSGKEFKCKVNNKDLPAPI ERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEW TNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSWHE GLHNHHTTKSFSRTPGK
[0340] Human IgGl KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE 62
[0341] VTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLT
[0342] Fc
[0343] VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0344] Human IgGl KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE 63
[0345] VTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLT
[0346] Fc variant
[0347] VLHQDWLNGKEYKCRVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0348] Human IgG2 KVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCV 64
[0349] WDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRWSVLTWHQ
[0350] Fc
[0351]
[0352] #15201735vlDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0353] Human IgG3 KVDKRVELKTPLGDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVF 65
[0354] LFPPKPKDTLMI SRTPEVTCVWDVSHEDPEVQFKWYVDGVEVHNAKTK
[0355] Fc
[0356] LREEQYNSTFRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRYT QKSLSLSPGK
[0357] Human IgG4 KVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTC 66
[0358] WVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRWSVLTVLH
[0359] Fc
[0360] QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS RLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0361] Human KSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSL 67
[0362] HRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRD
[0363] IgGAl Fc
[0364] LCGCYSVSSVLSGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFR PEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKY LTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFT QKTIDRLAGKPTHVNVSWMAEVDGTCY
[0365] Human KSVTCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSE 68
[0366] ANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPG
[0367] IgGA2 Fc
[0368] CAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEEL ALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGT TTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTH VNVSWMAEVDGTCY
[0369] Human IgM KSRVTISVDTSKKQLSLKLSSVNAADTAVYYCARVITRASPGTDGRYGM 69
[0370] DVWGQGTTVTVSSGSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPD
[0371] Fc
[0372] SITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEH WCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLIC QATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLT IKESDWLSQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFA SIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNAT FSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPD VYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVT SAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCWAHEALPNRVTERT VDKSTGKPTLYNVSLVMSDTAGTCY
[0373] Human IgE VAHTPSSTDWVDNKTFSVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLC 70
[0374] LVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKH
[0375] Fc
[0376] WLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRK SPTITCLWDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTS TLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFAT PEWPGSRDKRTLACLIQNFMPEDI SVQWLHNEVQLPDARHSTTQPRKTK GSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK
[0377] Human IgD KCWQHTASKSKKEIFRWPESPKAQASSVPTAQPQAEGSLAKATTAPAT 71
[0378] TRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDL
[0379] Fc
[0380] WLRDKATFTCFWGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQS QHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLN LLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPP QPRSTTFWAWSVLRVPAPPSPQPATYTCWSHEDSRTLLNASRSLEVSY
[0381]
[0382] #15201735vlLAMTPLIPQSKDENSDDYTTFDDVGSLWTTLSTFVALFILTLLYSGIVT
[0383] FIKVK
[0384]
[0385] EXAMPLES
[0386] Example 1. Design and testing of synthetic immune cell engagers.
[0387] Anti-G4S, anti-camelid (anti-VHH) synthetic immune cell engagers (“SHARKs”) were co-incubated for 16 hours with second generation CAR-T cell constructs in Jurkat cells with an NF AT GFP reporter that produces green fluorescent protein (GFP) upon T-cell activation. Jurkat cells were evaluated by flow cytometry for fraction expressing GFP. Untransduced T cells were used as controls. Increases in NF AT expression (as measured by GFP expression) were observed in all transduced CAR-T cells incubated with synthetic immune cell engagers - with the exception of negative controls - indicating that immune cell engagers were binding to the CAR-T cells (FIGs. 1, FIG. 16, and FIG. 4). The percentage of viable CAR+ cells decreased following co-culture with increasing concentrations of anti-G4S synthetic immune cell engagers (FIG. 3).
[0388] CD69, a marker of T cell activation, and CD 107 a, a marker of degranulation, were also evaluated by flow cytometry. Co-cultured CAR-T cells upregulated CD69 and CD107a following co-culture with synthetic immune cell engagers, and absolute T cell numbers decreased, again indicating that engagers were binding CAR-T cells (FIG. 2, FIGs. 5-7D).
[0389] Anti-TRBC 1 immune cell engagers were evaluated for their ability to activate Jurkat T cells, with activation being indicative of binding of Jurkat T cells by the immune cell engagers. Anti-TRBC 1 immune cell engagers were serially diluted (0.21 mg / mL undiluted concentration) and incubated with Jurkat T cells. At low dilutions of anti-TRBCl immune cell engagers, there was an increase in NF AT expression and decrease in the percentage of viable cells compared to a negative control immune cell engager (anti-camelid) (FIGs. 8A-8B). Anti-TRBCl immune cell engagers were observed to more potentially induce NF AT expression, cell death, degranulation (as measured by CD107a expression), and activation (as measured by CD69 expression) compared to an anti-TRBCl antibody (FIGs. 8C-8F). NFAT expression was confirmed by fluorescent imaging of GFP (FIG. 8G).
[0390] Next, the functionality of synthetic immune cell engagers were tested in vivo.
[0391] Immunodeficient NSG mice were engrafted with 1 x 106Jurkat cells expressing a click beetle green (CBG) fluorescent reporter via tail vein injection on day -7 (FIG. 14A). On day 0, mice received daily intravenous injections of immune cell engagers at different doses. Total body
[0392] #15201735vlluminescence was quantified at days 2, 4, 6, and 8 post- injection. Mice receiving anti-TRBCl immune cell engagers had a significantly lower tumor bioluminescence compared to mice that received phosphate buffer saline (PBS) only, indicating that the synthetic immune cell engagers successfully redirected the Jurkat cells to kill each other, thereby decreasing the tumor bioluminescence (FIGs. 9 and 14B). There were also significantly fewer circulating tumor cells in anti-TRBCl immune cell engager- treated mice (FIG. 14C), and body weight was maintained compared to mice injected with saline (PBS) (FIG. 14D). Mice receiving anti-TRBCl immune cell engagers lived significantly longer than mice receiving PBS (FIG. 14E).
[0393] In another experiment, Jurkat NF AT reporter cells were transduced with a CAR containing monomeric streptavidin as the binding domain. Cells were treated with increasing concentrations of biotin-PEGx-biotin (PEGylated biotin) immune cell engagers (FIGs. 10A-10B). Biotin-PEG12-biotin immune cell engagers resulted in the highest CAR- Jurkat NFAT-reporter activity (FIGs. 10C-10D).
[0394] Anti- Whitlow immune cell engagers were next tested against Jurkat cells bearing CARs containing a G4S (non- Whitlow) or Whitlow linker. CAR-T cells were incubated with antiWhitlow immune cell engagers for 16 hours, and activation, as measured by NF AT GFP expression, was evaluated by flow cytometry. Only CAR-T cells bearing Whitlow-positive CARs (Breyanzi) were activated in response to the immune cell engagers (FIGs. 11A-11B and 27B). Whitlow-linker CAR-T cells also produced Granzyme B and TNF-a after 24 hours of coincubation with anti-Whitlow immune cell engagers, while G4S-linker CAR-T cells did not (FIGs. 11C-11D, FIGs. 18A-18E, FIGs. 27C-27I).
[0395] Anti-TRBCl immune cell engagers were tested against TRBC1+ CAR-T cells. Bulk T cells underwent bead-based isolation for TRBC1, followed by standard CAR expression using a claudin 18.2-targeted second generation CAR. CAR-T cells were then exposed to anti-TRBCl immune cell engagers at various concentrations. Live cells, apoptosis (as measured by caspase-3 and -7 expression), degranulation (as measured by CD107a expression), and activation (as measured by CD69 expression) were evaluated by flow cytometry, and apoptosis was additionally evaluated by fluorescence. TRBC1+ CAR-T cells co-incubated with anti-TRBCl immune cell engagers had significantly decreased live cells and significantly increased apoptotic cells, degranulation, and activation compared to TRBC1+ CAR-T cells not co-incubated with anti-TRBCl immune cell engagers (FIGs. 12A-12E).
[0396] Heterodimeric immune cell engagers were also tested. Jurkat NFAT-GFP reporter cells were transduced with either a CD19-targeted CAR construct or a BCMA-targeted single domain
[0397] #15201735vlantibody (VHH) based on second generation CAR-T design. CAR-T cells or untransduced (CAR ) cells were then cultured alone or with anti-CD19 / anti-VHH immune heterodimeric cell engagers. Anti-CD19 CAR-T cells co-incubated with anti-CD19 / anti-VHH heterodimeric immune cell engagers exhibited significantly higher activation than all other tested conditions (FIG. 13).
[0398] It was next investigated whether SHARK molecules and antibodies activate CAR-T cells in cis, by clustering CAR molecules on the same cell, or in trans, by bridging CARs on neighboring CAR-T cells (exemplary schematics, FIGs. 19A-19B). Whitlow-linker CAR-T cells were split into two populations, labeled separately with CellTrace Violet or CellTrace Red, and then recombined at a 1:1 ratio. Cells were encapsulated into lipid droplets containing equimolar amounts (0.04 nM) of either anti-Whitlow SHARKS or anti-Whitlow antibodies, together with a fluorescent granzyme B substrate that fluoresces upon cleavage. If activation occurs in cis, granzyme B activity should be comparable in droplets containing single cells (only one dye) and in droplets containing two cells (both dye colors). By contrast, if activation is mediated in trans, granzyme B activity is expected to be enriched in droplets containing two cells, reflecting SHARK-driven CAR molecule bridging between adjacent CAR-T cells.
[0399] After incubation for 3, 6, or 24 hours, droplets were analyzed by flow cytometry (FIGs.
[0400] 19C-19E). Normalized transactivation analysis showed enhanced trans-activation induced by SHARKs compared to anti-Whitlow antibodies (FIG. 19F and 27K). Normalized transactivation was calculated as the difference between the percentage of granzyme B-positive droplets containing two cells (both dyes) and the sum of granzyme B-positive droplets containing only one dye or the other (%granzyme B-positive(both) - %granzyme B-positive(first dye) -%granzyme B-positive(second dye)).
[0401] The potential role of Fc-mediated effector functions of anti-CAR antibodies was next interrogated. NSG mice were injected with a toxic dose of CLDN18.2 CAR-T cells (3 x 106). Beginning the following day, mice received daily treatment with either 0.001 mg of anti-Whitlow linker antibodies or an Fc-silenced anti-Whitlow linker antibody bearing the LALAPG.NG mutations (L234A, L235A, P329G, N297G) (experimental schematic, FIGs. 20A and 26C). Whereas treatment with the Fc-competent antibody rescued mice from CAR-T-induced body weight loss and early mortality, untreated mice and mice receiving the Fc-silenced antibodies exhibited comparable weight loss and mortality and had comparable infiltration of CAR-T cells in the glandular stomach (FIGs. 20B-20C and 26D-26G). These results indicate that Fc effector functions are required for anti-CAR antibody-mediated protection and suggest
[0402] #15201735vlthat anti-CAR antibody therapy may be ineffective in settings of impaired Fc effector activity, such as severe cytopenia.
[0403] The efficacy of anti-Whitlow SHARK molecules delivered via a subcutaneously implanted osmotic pump was next tested. NSG mice were injected with a toxic dose of CLDN18.2 CAR-T cells (4 x 106). Beginning the following day, mice received saline (sham) or anti-Whitlow linker SHARKS (0.01 mg / day) delivered via the osmotic pump, subcutaneously implanted in the flank (FIG. 20D and 27L). Survival, body weight, and quantification of circulating CAR-T cells demonstrated the protective effect of anti-Whitlow linker SHARKS administered via the osmotic pump (FIGs. 20D-20G).
[0404] The experiment using CLDN18.2 CAR-T cells to induce toxicity was repeated using Fc-silenced anti-Whitlow linker antibodies in lieu of SHARK molecules, which did not protect mice (FIGs. 20A-20C).
[0405] Functional Fc domains were next fused to SHARK molecules to test their effect on halflife and Fc-mediated effector functions to further enhance CAR-T cell depletion (schematics, FIGs. 21A, 28A, and 28G). In a first test, NSG mice were injected with a toxic dose of CLDN18.2 CAR-T cells (3 x 106). The following day, mice received either sham or anti-Whitlow linker SHARK-Fc molecules, administered at an equimolar dose corresponding to 0.003 mg / day of SHARK via an osmotic pump subcutaneously implanted in the flank (FIG. 28B). Whereas untreated mice exhibited progressive body weight loss and succumbed within two weeks of CAR-T cell infusion, SHARK-Fc-treated mice showed no signs of toxicity and survived long term (FIGs. 21B, 21G, and 28C). Additionally, circulating CAR-T cells and the presence of CD3+ cells in the glandular stomach was significantly reduced in SHARK-Fc treated mice (FIGs. 21H and 28D-28F).
[0406] To validate the anti-Whitlow SHARK-Fc efficacy in an independent CAR-T cell toxicity model, an anti-RORl CAR-T cell model was next tested. NSG mice were left untreated (UT) or injected with 3 x 106anti-RORl CAR-T cells. Body weight and survival analysis demonstrated severe weight loss and 100% mortality in anti-RORl CAR-T cell treated mice within 70 days of engraftment (FIGs. 21C-21D). In a parallel experiment, NSG mice were injected with 3 x 106anti-RORl CAR-T cells co-expressing firefly luciferase, to enable in vivo tracking by bioluminescence imaging (BLI). CAR-T cells rapidly accumulated in anatomical regions consistent with the lungs and kidneys and subsequently disseminated systematically, with prominent signals observed in the abdominal region (FIG. 21E). Immunohistochemistry
[0407] #15201735vlconfirmed extensive CAR-T cell infiltration in the lungs, liver spleen, and kidneys of anti-RORl CAR-T-treated mice (FIG. 21F).
[0408] The efficacy of anti-Whitlow linker SHARK-Fc molecules was next validated in an anti-GD2 (E101K) CAR-T cell toxicity model. NSG mice were injected with a toxic dose of high-affinity anti-GD2 (E101K) CAR-T cells (3 x 106) and, beginning the following day, mice received either sham or anti-Whitlow linker SHARK-Fc molecules, administered at an equimolar dose corresponding to 0.003 mg / day of SHARK via an osmotic pump subcutaneously implanted in the flank (FIG. 28J). Whereas untreated mice developed rapid body weight loss and succumbed within one week of CAR-T cell infusion, SHARK-Fc-treated mice showed no signs of toxicity and survived long term (FIG. 211 and 28K). Additionally, untreated mice showed sustained persistence of circulating CAR-T cells, whereas SHARK-Fc-treated mice showed no detectable CAR-T cells throughout the entire observation period, similar to the anti-RORl CAR-T cell model (FIG. 21J and 28L). SHARK-Fc-treated mice also showed reduced infiltration of CD3+ cells in the brain compared to mice that did not receive SHARK-Fc molecules (FIGs. 28M-28N).
[0409] Next generations of previously-tested SHARK models were next designed and tested. Anti-VHH SHARK molecules bearing different VHH binders were compared in their ability to bind and activate anti-CLDN18.2 CAR Jurkat cells, with one binder inducing higher CAR activation (FIG. 22). Anti-Whitlow linker SHARK molecules bearing different Whitlow linker binders were also tested, with one binder inducing strong, selective activation of Whitlow linkerbearing CAR Jurkat cells, while the other binder exhibited modest activation (FIG. 23).
[0410] Anti-TRBC2 SHARK molecules were tested for their efficacy and specificity. AntiCD 19 CAR-T cells were treated with anti-TRBC2 SHARK molecules for 24 hours and then analyzed by flow cytometry for expression of TRBC1, TRBC2, and CD69. Quantification of absolute numbers of live TRBC1+ and TRBC2+ T cells showed selective induction of cell death within the TRBC2+population following anti-TRBC2 SHARK treatment (FIG. 24A), as well as selective activation of TRBC2+T cells (FIGs. 24B and 29A).
[0411] Two different anti-TRBC2 SHARK clones were tested for their cytotoxic effects on TRBC2+ T cells in a parallel to testing of anti-TRBCl SHARKS against TRBC1+ T cells. The anti-TRBCl SHARK and one anti-TRBC2 SHARK clone demonstrated strong cytotoxic effects against T cells expressing their respective targets (FIGs. 30A-30B).
[0412] It was hypothesized that SHARK molecules promote immunological synapse formation between normal T cells and leukemia cells, thereby enhancing T cell-mediated killing of
[0413] #15201735vlmalignant cells. To test this hypothesis, a real-time cytotoxicity assay (Incucyte) was performed in which Jurkat T-ALL cells were cultured with anti-TRBCl SHARK molecules alone, T cells alone, or a combination of T cells and anti-TRBCl SHARKS. Whereas T cells alone has no effect on Jurkat T-ALL growth, anti-TRBCl SHARK treatment significantly inhibited T-ALL cell expansion, with the strongest anti-tumor effect observed in the combination group (FIG. 25A), indicating that anti-TRBCl SHARK molecules facilitate productive T cell-tumor cell synapse formation and enhances T cell-mediated cytotoxicity.
[0414] SHARK-dependent cytotoxicity was next modeled in vivo. NSG mice were intravenously injected with 1 x 106Jurkat T-ALL cells. One week later, mice received an intravenous infusion of 3 x 106untransduced (UTD) human T cells. Beginning the following day, mice were treated with daily intravenous injections of anti-TRBCl SHARK molecules (0.001 mg / day). Peripheral blood was collected at 7, 14, and 21 days after T cell infusion (experimental schematic, FIG. 25B). Quantification of circulating T-ALL Jurkat cells in peripheral blood demonstrated complete clearance of leukemia cells in SHARK-treated mice (FIG. 25C), and analysis of the T cell compartment 14 days after T cell infusion revealed that anti-TRBCl SHARK treatment selectively depleted TRBC1+ T cells in vivo (FIG. 25D).
[0415] Taken together, the data illustrate that the synthetic immune cell engagers described herein can activate target immune effector cells, enhance bystander T cell activity, induce immune effector cell killing, and are protective in against toxic CAR-T cells in vivo (putative mechanisms shown in FIG. 29A and FIG. 17).
[0416] Example 2. Fratricide by design-selective T cell elimination for CAR-T cell toxicity and T-cell malignancies.
[0417] Chimeric antigen receptor (CAR)-T cell therapies have transformed cancer care but are limited by life-threatening toxicides, including cytokine release syndrome, neurotoxicity, and emerging syndromes such as IEC-EC and IEC-HS, which occur in up to three-quarters of patients. Existing safety switches are limited by reliance on additional genetic engineering or host Fc-mediated clearance, the latter of which is ineffective in cytopenic states that are common after CAR-T infusion. This Example describes synthetic immune cell engagers called SHARKS (Synthetic Homodimer Activating Reciprocal Killing), a class of dimeric biologies that eliminate pathogenic T cells via induced fratricide. SHARKS enforce trans CAR cross-linking between neighboring T cells, triggering immunological synapse formation and reciprocal killing, independent of host effector function. SHARKS demonstrated potent activity across diverse CAR
[0418] #15201735vlconstructs, including all FDA-approved architectures, and abrogated toxicity in murine gastric, pulmonary, and neurologic models, both before and after symptom onset. Fc-silent antibodies were ineffective, consistent with previously reported clinical failure of cetuximab-mediated clearance. SHARKS also selectively eradicated TRBC 1 / 2-restricted T-cell malignancies. These findings establish receptor-directed fratricide as a broadly applicable strategy to enhance the safety and therapeutic scope of cellular immunotherapies and T-cell malignancies.
[0419] First it was established herein that CAR molecules contain multiple targetable extracellular epitopes that could be exploited by antibody-based approaches as off-the-shelf safety switches. Using anti-linker antibodies targeting the Whitlow linker, it was demonstrated that conventional antibodies can deplete pathogenic CLDN18.2 CAR-T cells and mitigate on-target, off-tumor gastric toxicity. It was also observed that this mechanism is facilitated by intact Fc-mediated effector function. Consistent with prior clinical findings of the inventors, Fc-inactivated antibodies fail to eliminate CAR-T cells or protect against toxicity, highlighting a fundamental limitation of antibody-based depletion strategies in cytopenic patients (FIGs. 26A-26G).
[0420] To develop an off-the-shelf safety switch for CAR-T cell therapy that was not dependent on Fc function, it was hypothesized herein that exploit CAR cross-linking could be exploited to induce CAR-T cell fratricide, which would inherently not be subject to other effector cell functions. Through systematic interrogation of receptor spacing, it was demonstrated that antibody-mediated cross-linking is geometrically suboptimal, whereas bispecific T cell engagerlike spacing maximizes CAR activation. Building on this insight, SHARK molecules, or dimeric molecules capable of enforcing optimal trans CAR engagement, were engineered. SHARKS induced robust CAR activation, degranulation, and selective fratricide, outperforming clone-matched antibodies. Using a microfluidic droplet co-encapsulation system, it was directly demonstrated that SHARKS function through trans activation between neighboring cells.
[0421] Importantly, SHARKS lacking Fc domains exerts full in vivo activity, rapidly depleting CAR-T cells and preventing lethal toxicity (FIGs. 27A-27O).
[0422] To enhance pharmacokinetics, translational feasibility, and overall in vivo potency, SHARK-Fc fusion proteins incorporating a murine IgG2a domain were next engineered. This design was intended not only to extend serum half-life and improve biodistribution, but also to optionally leverage Fc-mediated effector functions in immune-competent settings, thereby providing a dual-mechanism platform that combines intrinsic fratricide with conventional immune clearance when available. Importantly, SHARK-Fc retained the core / / r -activating
[0423] #15201735vlmechanism of SHARKS, ensuring activity even in cytopenic environments where Fc-dependent pathways are compromised. Across three independent models of on-target / off-tumor toxicity — gastric (CLDN18.2), pulmonary (ROR1), and neurologic (GD2) — SHARK-Fc completely abrogated toxicity and suppressed CAR-T expansion. Notably, SHARK-Fc remained effective even when administered after the onset of clinical toxicity, an important feature for real- world deployment in patients presenting with established adverse events. Finally, this platform was extended to camelid-based CAR constructs, including ciltacabtagene ciloleucel-like BCMA-targeting CAR-T cells (FIGs. 28A-28T). Ciltacabtagene ciloleucel is a camelid-based, FDA-approved CAR-T therapy in broad clinical use that is also associated with life-threatening neurologic and intestinal toxicides, underscoring the need for effective and broadly applicable safety switches in this setting, which the SHARK molecules engineered herein could provide.
[0424] Finally, to demonstrate that SHARKS represent a generalizable platform beyond CAR-T toxicity, SHARKs were developed targeting TRBC1 for the treatment of T-cell malignancies. TRBC1 -directed CAR-T cell therapies have shown promising preclinical activity but have encountered clinical limitations, in part due to “reverse killing,” whereby TRBC1 cells eliminate CAR-T cells following immune synapse formation. Leveraging the mutually exclusive expression of TRBC1 and TRBC2 within the T-cell receptor p chain repertoire, this strategy enabled selective targeting of clonal malignant populations while preserving a substantial fraction of normal T cells. It was demonstrated that TRBC1 -directed SHARKs induce TCR cross -linking, activation, and fratricide analogous to their activity in CAR-T systems, resulting in effective tumor control and prolonged survival in T-ALL models. Importantly, in the presence of healthy polyclonal T cells, SHARK treatment selectively eliminated malignant and healthy TRBC I cells while sparing the TRBC2+compartment, thereby preserving a functional T-cell repertoire (FIGs. 29A-29H).
[0425] Taken together, the data demonstrate that the molecules provided herein provide both a robust safety switch to protect against CAR-T cell toxicides as well a novel treatment for T-cell malignancies.
[0426] EQUIVALENTS AND SCOPE
[0427] While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and / or structures for
[0428] #15201735vlperforming the function and / or obtaining the results and / or one or more of the advantages described herein, and each of such variations and / or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and / or configurations will depend upon the specific application or applications for which the inventive teachings is / are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
[0429] The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
[0430] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
[0431] In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of’ and “consisting essentially of’ shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
[0432] The terms “about” and “substantially” preceding a numerical value mean ±10% of the recited numerical value.
[0433] Where a range of values is provided, each value between and including the upper and lower ends of the range are specifically contemplated and described herein.
[0434] #15201735vl
Claims
CLAIMSWhat is claimed is:
1. A synthetic monospecific immune cell engager, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain and the second antigen-binding domain target the same immune cell antigen.
2. The synthetic monospecific immune cell engager of claim 1, wherein the synthetic monospecific immune cell engager does not comprise an Fc region.
3. The synthetic monospecific immune cell engager of claim 1 or 2, wherein the first antigen-binding domain and the second antigen-binding domain comprise the same amino acid sequence.
4. The synthetic monospecific immune cell engager of any one of claims 1-3, wherein the synthetic monospecific immune cell engager is a homodimeric immune cell engager.
5. The synthetic monospecific immune cell engager of any one of claims 1-4, wherein the first antigen-binding domain and the second antigen-binding domain are linked by a linker.
6. The synthetic monospecific immune cell engager of claim 5, wherein the linker comprises the amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 61.
7. The synthetic monospecific immune cell engager of any one of claims 1-6, wherein the immune cell antigen is an antigen expressed by a chimeric antigen receptor (CAR)-T cell, a T cell, a natural killer (NK) cell, a B cell, a macrophage, a mast cell, a neutrophil, a eosinophil, a basophil, a monocyte or a dendritic cell.
8. A synthetic monospecific immune cell engager comprising:a first antigen-binding domain comprising a VH, a (648)3 linker, and a VL;a G4S linker; anda second antigen-binding domain comprising a VH, a (648)3 linker, and a VL.#15201735vl9. The synthetic monospecific immune cell engager of any one of claims 1-7, wherein the immune cell antigen is a camelid, FMC63, a G4S linker, a Whitlow linker, T cell receptor constant P chain-1 (TRBC1), TRBC2, natural killer group 2 member D (NKG2D), CD16A, CD206, or CD163.
10. The synthetic monospecific immune cell engager of any one of claims 1-8, wherein the first antigen-binding domain and the second antigen-binding domain comprise BCMA, CD 19, or a peptide-MHC complex.
11. The synthetic monospecific immune cell engager of any one of claims 1-8, wherein the synthetic monospecific immune cell engager comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
12. The synthetic monospecific immune cell engager of any one of claims 1-8, wherein the synthetic monospecific immune cell engager comprises the amino acid sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
13. The synthetic monospecific immune cell engager of any one of claims 1 or 3-12, wherein the synthetic monospecific immune cell engager comprises an Fc domain.
14. The synthetic monospecific immune cell engager of claim 13, wherein the Fc domain does not comprise a silencing mutation.
15. The synthetic monospecific immune cell engager of claim 13, wherein the Fc domain is fused to the synthetic monospecific immune cell engager via a linker, optionally wherein the linker is a glycine / serine linker.
16. The synthetic monospecific immune cell engager of any one of claims 13-15, wherein the Fc domain is an IgG, IgA, IgD, IgE, or IgM Fc domain, optionally a human IgG, IgA, IgD, IgE, or IgM Fc domain.#15201735vl17. The synthetic monospecific immune cell engager of claim 16, wherein the IgG Fc domain is an IgGl, IgG2, IgG3, or an IgG4 Fc domain.
18. The synthetic monospecific immune cell engager of claim 16, wherein the IgA Fc domain is an IgAl or an IgA2 Fc domain.
19. The synthetic monospecific immune cell engager of any one of claims 13-18, wherein the Fc domain comprises an S239D mutation, an I332E mutation, an S239D / I332E mutation, a G236A mutation, and A330L mutation, a G236A / S239D / A330L / I332E mutation, an S298A / E333A / K334A mutation, an E345K mutation, an E430G mutation, an S440Y mutation, an E345K / E430G mutation, an E430G / S440Y mutation, or an E345K / E430G / S440Y mutation.
20. The synthetic monospecific immune cell engager of any one of claims 13-19, wherein the Fc domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 62-71.
21. The synthetic monospecific immune cell engager of any one of claims 15-20, wherein the Fc domain comprises the amino acid sequence of any one of SEQ ID NOs: 62-71.
22. The synthetic monospecific immune cell engager of any one of claims 13-21, wherein the synthetic monospecific immune cell engager comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 55, 58, or 60.
23. The synthetic monospecific immune cell engager of any one of claims 13-22, wherein the synthetic monospecific immune cell engager comprises the amino acid sequence of any one of SEQ ID NOs: 55, 58, or 60.
24. A polynucleotide encoding the synthetic monospecific immune cell engager of any one of claims 1-23.
25. A method of linking two or more immune effector cells, the method comprising contacting the two or more immune effector cells with a synthetic immune cell engager that#15201735vlcomprises a first antigen-binding domain that binds to a first immune effector cell antigen (IECA) and a second antigen-binding domain that binds to a second IECA.
26. The method of claim 25, wherein the first IECA and the second IECA each comprise one or more of a linker, a camelid, a T cell antigen, a chimeric antigen receptor (CAR)-T cell antigen, a natural killer (NK) cell antigen, a B cell antigen, a macrophage antigen, a mast cell antigen, a neutrophil antigen, a eosinophil antigen, a basophil antigen, a monocyte antigen and / or a dendritic cell antigen.
27. The method of claim 25 or 26, wherein the first IECA and the second IECA are the same.
28. The method of claim 25 or 26, wherein the first IECA and the second IECA are different.
29. The method of any one of claims 25-27, wherein the first antigen-binding domain and the second antigen-binding domain comprise the same amino acid sequence.
30. The method of any one of claims 25-29, wherein the first antigen-binding domain and the second antigen-binding domain are linked by a linker.
31. The method of claim 30, wherein the linker comprises the amino acid sequence of SEQ ID NO: 35 or 61.
32. The method of any one of claims 25-31, wherein contacting the two or more immune cells with the synthetic immune cell engager inactivates the two or more immune cells.
33. The method of any one of claims 25-32, wherein contacting the two or more immune cells with the synthetic immune cell engager induces death of the two or more immune cells.
34. A method of inducing immune effector cell death, the method comprising contacting two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain and a second antigen-binding domain.#15201735vl35. A method of inactivating two or more immune effector cells, the method comprising contacting the two or more immune effector cells with a synthetic immune cell engager that comprises a first antigen-binding domain and a second antigen-binding domain.
36. The method of claim 34 or 35, wherein the two or more immune effector cells are selected from the group consisting of a T cell, a CAR-T cell, a NK cell, a B cell, a macrophage, a mast cell, a neutrophil, a eosinophil, a basophil, a monocyte, and a dendritic cell.
37. A method of treating cell therapy-associated toxicity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a synthetic immune cell engager, wherein the synthetic immune cell engager comprises a first antigenbinding domain and a second antigen-binding domain.
38. The method of any one of claims 25-29, wherein the first antigen-binding domain and / or the second antigen-binding domain binds to a camelid, FMC63, a G4S linker, a Whitlow linker, T cell receptor constant P chain- 1 (TRBC1), TRBC2, natural killer group 2 member D (NKG2D), CD16A, CD206, or CD163.
39. The method of any one of claims 25-38, wherein the first antigen-binding domain and / or the second antigen-binding domain comprise BCMA, CD 19, or a peptide-MHC complex.
40. The method of any one of claims 25-39, wherein the synthetic immune cell engager comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
41. The method of any one of claims 25-40, wherein the synthetic immune cell engager comprises the amino acid sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 14, 16, 17, 20, 23, 26, 29, 31, 38, 41, 44, 47, 52, or 54.
42. The method of any one of claims 25-41, wherein the synthetic immune cell engager does not comprise an Fc region.#15201735vl43. The method of any one of claims 25-42, wherein the synthetic immune cell engager does not comprise more than two antigen-binding domains.
44. The method of any one of claims 25-41 or 43, wherein the synthetic immune cell engager comprises an Fc domain.
45. The method of claim 44, wherein the Fc domain does not comprise a silencing mutation.
46. The method of claim 45, wherein the Fc domain is fused to the synthetic immune cell engager via a linker, optionally wherein the linker is a glycine / serine linker.
47. The method of claim 45 or 46, wherein the Fc domain is an IgG, IgA, IgD, IgE, or IgM Fc domain, optionally a human IgG, IgA, IgD, IgE, or IgM Fc domain.
48. The method of claim 47, wherein the IgG Fc domain is an IgGl, IgG2, IgG3, or an IgG4 Fc domain.
49. The method of claim 47, wherein the IgA Fc domain is an IgAl or an IgA2 Fc domain.
50. The method of any one of claims 44-49, wherein the Fc domain comprises an S239D mutation, an I332E mutation, an S239D / I332E mutation, a G236A mutation, and A330L mutation, a G236A / S239D / A330L / I332E mutation, an S298A / E333A / K334A mutation, an E345K mutation, an E430G mutation, an S440Y mutation, an E345K / E430G mutation, an E430G / S440Y mutation, or an E345K / E430G / S440Y mutation.
51. The method of claim of any one of claims 44-50, wherein the Fc domain comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 62-71.
52. The method of any one of claims 44-51, wherein the Fc domain comprises the amino acid sequence of any one of SEQ ID NOs: 62-71.#15201735vl53. The method of any one of claims 44-52, wherein the synthetic immune cell engager comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 55, 58, or 60.
54. The method of any one of claims 44-52, wherein the synthetic immune cell engager comprises the amino acid sequence of any one of SEQ ID NOs: 55, 58, or 60.
55. A method of treating a T cell malignancy in a subject in need thereof, the method comprising administering a synthetic monospecific immune cell engager of any one of claims 1-23 to the subject.
56. A synthetic monospecific immune cell engager, comprising a first antibody fragment linked to a second antibody fragment with a first linker, wherein the first antibody fragment and the second antibody fragment target the same immune cell antigen.
57. A synthetic monospecific immune cell engager, comprising a first antibody fragment covalently linked to a second antibody fragment with a first linker, wherein the first antibody fragment and the second antibody fragment target the same immune cell antigen, optionally wherein the first antibody fragment and the second antibody fragment have the same sequence.
58. The synthetic monospecific immune cell engager of claim 56 or claim 57, wherein the first linker is a flexible linker, optionally wherein the flexible linker is a peptide linker.
59. The synthetic monospecific immune cell engager of any one of claims 56-58, wherein the first linker comprises fewer than 50 amino acids or fewer than 10 amino acids.
60. The synthetic monospecific immune cell engager of any one of claims 56-59, wherein the first antibody fragment and / or the second antibody fragment is covalently linked to an Fc region with a second linker.
61. The synthetic monospecific immune cell engager of any one of claims 56-59, wherein the first antibody fragment or the second antibody fragment is covalently linked to an Fc region with a second linker, optionally wherein the second linker is a peptide linker.#15201735vl62. A method of treating cell therapy-associated toxicity in a subject in need thereof, the method comprising administering to the subject a the synthetic immune cell engager of any one of claims 56-61, wherein the first antibody fragment and the second antibody fragment both bind to the same cell surface protein of the cell therapy.#15201735vl
